BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
Number Citing Articles
1 Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
3 Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, Tanaka J, Izumi N, Kanto T. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2021;56:470-8. [PMID: 33791882 DOI: 10.1007/s00535-021-01782-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 García-Cortés M, Ortega-Alonso A, Andrade RJ. Safety of treating acute liver injury and failure. Expert Opin Drug Saf 2021;:1-13. [PMID: 34254839 DOI: 10.1080/14740338.2021.1955854] [Reference Citation Analysis]
5 Papaluca T, Sinclair M, Gow P, Pianko S, Sievert W, Arachchi N, Cameron K, Bowden S, O'Keefe J, Doyle J, Stoove M, Hellard M, Iser D, Thompson A. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Liver Int 2019;39:2285-90. [PMID: 31355968 DOI: 10.1111/liv.14201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, Duffell E, Tammi T, Schatz E. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J 2020;17:89. [PMID: 33213481 DOI: 10.1186/s12954-020-00439-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
8 Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A. SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells. 2019;8. [PMID: 30987413 DOI: 10.3390/cells8040313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Forns X, Sarrazin C. Treatment of chronic hepatitis C. J Hepatol 2018;69:544-6. [PMID: 29891100 DOI: 10.1016/j.jhep.2018.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 El-sayed MH, Indolfi G. Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Semin Liver Dis 2020;40:213-24. [DOI: 10.1055/s-0040-1708812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Niu LJ, Zhang YM, Huang T, Sun XF, Luo SX. Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression. Ann Transl Med 2021;9:137. [PMID: 33569439 DOI: 10.21037/atm-20-7787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Seo HY, Seo MS, Yoon SY, Choi JW, Ko SY. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. Korean J Intern Med 2020;35:559-65. [PMID: 31064176 DOI: 10.3904/kjim.2018.338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pérez-garcía A, Aguinaga A, Navascués A, Castilla J, Ezpeleta C. Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus. International Journal of Infectious Diseases 2019;89:131-6. [DOI: 10.1016/j.ijid.2019.09.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
16 Wilton J, Wong S, Yu A, Ramji A, Cook D, Butt ZA, Alvarez M, Binka M, Darvishian M, Jeong D, Bartlett SR, Pearce ME, Adu PA, Yoshida EM, Krajden M, Janjua NZ. Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study. Open Forum Infect Dis. 2020;7:ofaa055. [PMID: 32154326 DOI: 10.1093/ofid/ofaa055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
17 Liu YC, Jeng WJ, Cheng YT, Hsieh YC, Teng W, Chen YC, Lin CY, Chien RN, Sheen IS. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (Baltimore) 2020;99:e21898. [PMID: 32925725 DOI: 10.1097/MD.0000000000021898] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Kaohsiung J Med Sci. 2021;37:334-345. [PMID: 33151016 DOI: 10.1002/kjm2.12315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J. Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C. Cancers (Basel) 2020;12:E2602. [PMID: 32933027 DOI: 10.3390/cancers12092602] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Picchio CA, Lens S, Hernandez-Guerra M, Arenas J, Andrade RJ, Crespo J, García-Samaniego J, Romero-Gómez M, Turnes J, Calleja JL, Simón MÁ, White TM, Riveiro-Barciela M, Pocurull A, Morales-Arraez D, Gómez A, Buti M, Lazarus JV. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Sci Rep 2021;11:24133. [PMID: 34921156 DOI: 10.1038/s41598-021-01885-0] [Reference Citation Analysis]
21 Yoo J, Lee JM, Joo I, Yoon JH. Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography. 2020;39:52-59. [PMID: 31623416 DOI: 10.14366/usg.19013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, Esteban JI, Quer J. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist 2019;12:947-55. [PMID: 31118701 DOI: 10.2147/IDR.S195441] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Defrancesco I, Zerbi C, Rattotti S, Merli M, Bruno R, Paulli M, Arcaini L. HCV infection and non-Hodgkin lymphomas: an evolving story. Clin Exp Med 2020;20:321-8. [PMID: 32052244 DOI: 10.1007/s10238-020-00615-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
25 Toma L, Stanciu AM, Zgura A, Bacalbasa N, Diaconu C, Iliescu L. Electrocardiographic Changes in Liver Cirrhosis-Clues for Cirrhotic Cardiomyopathy. Medicina (Kaunas) 2020;56:E68. [PMID: 32050594 DOI: 10.3390/medicina56020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Cardozo EF, Ji D, Lau G, Schinazi RF, Chen GF, Ribeiro RM, Perelson AS. Disentangling the lifespans of hepatitis C virus-infected cells and intracellular vRNA replication-complexes during direct-acting anti-viral therapy. J Viral Hepat 2020;27:261-9. [PMID: 31670859 DOI: 10.1111/jvh.13229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
28 Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother 2020;75:3303-10. [PMID: 32766700 DOI: 10.1093/jac/dkaa299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
30 Corma-gómez A, Morano L, Téllez F, Rivero-juárez A, Real LM, Alados JC, Ríos-villegas MJ, Vera-méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33:1167-74. [DOI: 10.1097/qad.0000000000002186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Boyd A, Miailhes P, Chas J, Valantin MA, Yazdanpanah Y, Rosenthal E, Chevaliez S, Piroth L, Rougier H, Peytavin G, Pialoux G, Girard PM, Lacombe K. Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. J Antimicrob Chemother 2020;75:1961-8. [PMID: 32306039 DOI: 10.1093/jac/dkaa091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Gaspar R, Liberal R, Tavares J, Morgado R, Macedo G. HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. World J Hepatol 2020; 12(12): 1314-1325 [PMID: 33442457 DOI: 10.4254/wjh.v12.i12.1314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Abadía M, Montes ML, Ponce D, Froilán C, Romero M, Poza J, Hernández T, Fernández-Martos R, Olveira A, on behalf of the “La Paz Portal Hypertension” Study Group Investigators. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis. World J Gastroenterol 2019; 25(21): 2665-2674 [PMID: 31210717 DOI: 10.3748/wjg.v25.i21.2665] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut Liver 2020;14:775-82. [PMID: 32000468 DOI: 10.5009/gnl19260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
36 Huhn GD, Ramgopal M, Jain MK, Hinestrosa F, Asmuth DM, Slim J, Goldstein D, Applin S, Ryu JH, Jiang S, Cox S, Das M, Nguyen-Cleary T, Piontkowsky D, Guyer B, Rossaro L, Haubrich RH. HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS One 2020;15:e0224875. [PMID: 31995556 DOI: 10.1371/journal.pone.0224875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN, Chayama K. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. Clin J Gastroenterol 2020;13:267-70. [PMID: 31463795 DOI: 10.1007/s12328-019-01039-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J 2021;18:69. [PMID: 34193156 DOI: 10.1186/s12954-021-00519-y] [Reference Citation Analysis]
39 Yeh ML, Yu ML. Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey". J Hepatol 2020;73:462. [PMID: 32327360 DOI: 10.1016/j.jhep.2020.03.041] [Reference Citation Analysis]
40 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 A H, L M, Am J, M M, Gp A, S V. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis. Int J Drug Policy 2021;:103342. [PMID: 34210551 DOI: 10.1016/j.drugpo.2021.103342] [Reference Citation Analysis]
42 Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, Sanpajit T, Sutthivana C, Bunchorntavakul C, Sobhonslidsuk A, Chonprasertsuk S, Siripipattanamongkol C, Sethasine S, Tanwandee T; THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC Gastroenterol 2020;20:47. [PMID: 32138687 DOI: 10.1186/s12876-020-01196-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis 2019;220:557-66. [PMID: 30957170 DOI: 10.1093/infdis/jiz154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
44 Calça R, Jorge C, Lebre L, Cacheira E, Querido S, Nascimento C, Adragão T, Bruges M, Weigert A, Machado D. Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus. Nefrología (English Edition) 2020;40:675-6. [DOI: 10.1016/j.nefroe.2020.11.006] [Reference Citation Analysis]
45 El-garawani I, Hassab El-nabi S, Gadallah M, Abdelsameea E. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients. Immunological Investigations 2021;50:12-22. [DOI: 10.1080/08820139.2020.1722158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
46 Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut Liver 2021;15:440-50. [PMID: 32839365 DOI: 10.5009/gnl19393] [Reference Citation Analysis]
47 Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology. 2020;71:422-430. [PMID: 31220349 DOI: 10.1002/hep.30830] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
48 Mucenic M, Brandão ABM, Marroni CA, Fleck Junior AM, Zanotelli ML, Leipnitz I, Meine MH, Kiss G, Martini J, Schlindwein ES, Costabeber AM, Sacco FKR, Rossato G, Cantisani GPC. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review. Rev Inst Med Trop Sao Paulo 2019;61:e12. [PMID: 30785566 DOI: 10.1590/S1678-9946201961012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Schmidbauer C, Chromy D, Schmidbauer VU, Schwarz M, Jachs M, Bauer DJM, Binter T, Apata M, Nguyen DT, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Breuer M, Strassl R, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. Liver Int 2021. [PMID: 34268869 DOI: 10.1111/liv.15018] [Reference Citation Analysis]
50 Ward KM, Falade-Nwulia O, Moon J, Sutcliffe CG, Brinkley S, Haselhuhn T, Katz S, Herne K, Arteaga L, Mehta SH, Latkin C, Brooner RK, Sulkowski MS. Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs. J Infect Dis 2021:jiab477. [PMID: 34543417 DOI: 10.1093/infdis/jiab477] [Reference Citation Analysis]
51 Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol 2021;6:448-58. [PMID: 33865507 DOI: 10.1016/S2468-1253(21)00031-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 McPherson S, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, Hallsworth K, Campbell M. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. BMJ Open Gastroenterol 2020;7:e000470. [PMID: 32847899 DOI: 10.1136/bmjgast-2020-000470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Barajas L, Steuer M, Amerson E. Variable clinical course of lichen planus following hepatitis C cure with direct-acting antivirals: A case series and literature review. J Am Acad Dermatol 2021;84:1142-6. [PMID: 32649959 DOI: 10.1016/j.jaad.2020.05.159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Marins EG, Krey N, Becker A, Melzer S, Hoppler M. Evaluation of the cobas® HCV test for quantifying HCV RNA in dried plasma spots collected using the cobas® Plasma Separation Card. J Virol Methods 2020;278:113820. [PMID: 31945390 DOI: 10.1016/j.jviromet.2020.113820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Martinello M, Bajis S, Dore GJ. Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation. Gastroenterol Clin North Am 2020;49:253-77. [PMID: 32389362 DOI: 10.1016/j.gtc.2020.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH;  REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587-598. [PMID: 31463665 DOI: 10.1007/s12072-019-09974-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
57 Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; Real-World Evidence from the Asia Liver Consortium Investigators. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis 2020;71:2840-8. [PMID: 31777940 DOI: 10.1093/cid/ciz1160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
58 Piecha F, Gänßler JM, Jordan S, Ergen C, Ittrich H, Kluwe J, Pischke S, Lohse AW, Schulze Zur Wiesch J. Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C? Hepatol Commun 2019;3:614-9. [PMID: 31061950 DOI: 10.1002/hep4.1337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. Medicine (Baltimore) 2018;97:e13383. [PMID: 30557991 DOI: 10.1097/MD.0000000000013383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ranjbar Kermani F, Amini-kafiabad S, Mousavi Hosseini K, Maghsudlu M, Sharifi Z, Mansournia MA. Look-Back Study of Transfusion-Transmitted Hepatitis C Virus Infection in Iran. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.108002] [Reference Citation Analysis]
61 Kang Q, Chen J, Luo H, Tan N, Gao H, Zhang X, Yu M, Liu D, Xi H, An Y, Han Y, Cheng R, Xu X. Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication. Dis Markers 2020;2020:8539804. [PMID: 33082884 DOI: 10.1155/2020/8539804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Danese S, D’haens G, Eckmann L, Faubion WA, Feagan BG, Jairath V, Ma C, Mcgovern D, Panes J, Sandborn WJ, Silverberg MS, Vermeire S; Alimentiv Translational Research Consortium (ATRC). Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00574-7] [Reference Citation Analysis]
63 Musialik J, Kolonko A, Kwiecień K, Owczarek AJ, Więcek A. Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation. Transpl Infect Dis 2019;21:e13090. [PMID: 30972854 DOI: 10.1111/tid.13090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Craviotto V, Lamonaca L, Aghemo A, Lleo A. No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. Liver Int 2018;38:2342-2342.. [PMID: 30218615 DOI: 10.1111/liv.13961] [Reference Citation Analysis]
65 Silva IPL, Batista AD, Lopes EP, Filgueira NA, Carvalho BT, Santos JC, Medeiros TB, Melo CRL, Lima MS, Lima K, Lacerda C, Lacerda HR. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil. Rev Inst Med Trop Sao Paulo 2021;63:e6. [PMID: 33533809 DOI: 10.1590/S1678-9946202163006] [Reference Citation Analysis]
66 Yadav DK, Zhang Q, Bai X, Li E, Liang T. Liver Transplantation for Alcohol-Related Liver Disease (ARLD): An Update on Controversies and Considerations. Can J Gastroenterol Hepatol 2020;2020:8862152. [PMID: 33014915 DOI: 10.1155/2020/8862152] [Reference Citation Analysis]
67 Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-sobol H, Mo H, Brainard DM, Yang Y, Dao L, Wang G, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology 2019;4:127-34. [DOI: 10.1016/s2468-1253(18)30343-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 16.3] [Reference Citation Analysis]
68 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
69 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
70 Celsa C, Stornello C, Giuffrida P, Giacchetto CM, Grova M, Rancatore G, Pitrone C, Di Marco V, Cammà C, Cabibbo G. Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence. Ann Hepatol 2021;:100568. [PMID: 34699987 DOI: 10.1016/j.aohep.2021.100568] [Reference Citation Analysis]
71 Velásquez-Orozco F, Rando-Segura A, Martínez-Camprecios J, Salmeron P, Najarro-Centeno A, Esteban À, Quer J, Buti M, Pumarola-Suñe T, Rodríguez-Frías F. Utility of the Cobas® Plasma Separation Card as a Sample Collection Device for Serological and Virological Diagnosis of Hepatitis C Virus Infection. Diagnostics (Basel) 2021;11:473. [PMID: 33800211 DOI: 10.3390/diagnostics11030473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Graupera I, Lammert F. Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden. Journal of Hepatology 2018;69:562-3. [DOI: 10.1016/j.jhep.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Masetti C, Lleo A, Colombo M, Colombo M, Aghemo A. Postsustained Virological Response Management in Hepatitis C Patients. Semin Liver Dis 2020;40:233-9. [PMID: 32107758 DOI: 10.1055/s-0040-1702944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Nakashima M, Toyoda H, Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T. Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection. Hepatol Res 2019;49:512-20. [PMID: 30628746 DOI: 10.1111/hepr.13311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
75 Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Chazouillères O, Mallat A, Grangé J, Attali P, d'Alteroche L, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-khac E, Bernard-chabert B, Zucman D, Di Martino V, Sutton A, Pol S, Nahon P. Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status. Journal of Hepatology 2020;73:1434-45. [DOI: 10.1016/j.jhep.2020.05.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
76 Busschots D, Toghanian S, Bielen R, Salomonsson S, Koc ÖM, Hendrickx G, Jadoul M, Nevens F, Sokal E, Brixko C, Peerlinck K, Apers L, Robaeys G, Lazarus JV. Eliminating viral hepatitis C in Belgium: the micro-elimination approach. BMC Infect Dis 2020;20:181. [PMID: 32106819 DOI: 10.1186/s12879-020-4898-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
77 Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 2019;71:666-72. [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
78 Calaf GM, Crispin LA, Muñoz JP, Aguayo F, Bleak TC. Muscarinic Receptors Associated with Cancer. Cancers 2022;14:2322. [DOI: 10.3390/cancers14092322] [Reference Citation Analysis]
79 Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin C, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial. Journal of Hepatology 2020;72:441-9. [DOI: 10.1016/j.jhep.2019.10.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 23.5] [Reference Citation Analysis]
81 Pereira Guedes T, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, Maia L, Moreira T, Manuel Ferreira J, Pedroto I. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. GE Port J Gastroenterol 2020;27:149-59. [PMID: 32509920 DOI: 10.1159/000503074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Martinello M, Matthews GV. Management of acute HCV in the era of direct-acting antivirals: implications for elimination. Lancet Gastroenterol Hepatol 2019;4:256-7. [PMID: 30660618 DOI: 10.1016/S2468-1253(19)30001-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
84 Pacella I, Cammarata I, Martire C, Brancaccio G, Gaeta GB, Barnaba V, Piconese S. CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis. Liver Int 2021;41:470-81. [PMID: 33159402 DOI: 10.1111/liv.14720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M, Zhuo Y, Fagiuoli S, Petersen J, Chhatwal J. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726. [PMID: 31189677 DOI: 10.1136/bmjopen-2018-026726] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
86 Koustenis KR, Anagnostou O, Kranidioti H, Vasileiadi S, Antonakaki P, Koutli E, Pantsas P, Deutsch M, Manolakopoulos S. Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting. Ann Gastroenterol. 2020;33:195-201. [PMID: 32127741 DOI: 10.20524/aog.2020.0449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-735. [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011] [Cited by in Crossref: 211] [Cited by in F6Publishing: 190] [Article Influence: 52.8] [Reference Citation Analysis]
88 Preda CM, Baicus C, Sandra I, Oproiu A, Manuc T, Constantinescu I, Gavrila D, Diculescu M, Dumitru R, Vasilescu C, Tieranu C, Istratescu D, Voiosu T, Manuc M. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy. United European Gastroenterol J 2019;7:699-708. [PMID: 31210948 DOI: 10.1177/2050640619841254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
89 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
90 Isfordink CJ, van de Laar TJW, Rebers SPH, Wessels E, Molenkamp R, Knoester M, Baak BC, van Nieuwkoop C, van Hoek B, Brakenhoff SM, Blokzijl H, Arends JE, van der Valk M, Schinkel J. Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infect Dis 2021;8:ofab006. [PMID: 33614815 DOI: 10.1093/ofid/ofab006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Sriphoosanaphan S, Thanapirom K, Suksawatamnuay S, Thaimai P, Sittisomwong S, Sonsiri K, Srisoonthorn N, Teeratorn N, Tanpowpong N, Chaopathomkul B, Treeprasertsuk S, Poovorawan Y, Komolmit P. Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy. BMC Gastroenterol 2020;20:346. [PMID: 33069226 DOI: 10.1186/s12876-020-01485-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol 2020;73:1548-56. [PMID: 32777323 DOI: 10.1016/j.jhep.2020.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
93 Ferrari D, Bagaglio S, Raso M, Galli L, Premaschi S, Messina E, Morsica G, Locatelli M, Uberti-Foppa C, Hasson H. A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. J Chromatogr B Analyt Technol Biomed Life Sci 2019;1120:1-7. [PMID: 31055190 DOI: 10.1016/j.jchromb.2019.04.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
94 Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SB, Schønning K, Bukh J, Gottwein JM. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. Journal of Hepatology 2019;70:388-97. [DOI: 10.1016/j.jhep.2018.10.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
95 Cenderello G, Taramasso L, Marra D, Orcamo P, Pasa A, Di Biagio A. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. Expert Rev Pharmacoecon Outcomes Res. 2019;19:189-193. [PMID: 30321071 DOI: 10.1080/14737167.2019.1537124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep 2020;3:e145. [PMID: 32270053 DOI: 10.1002/hsr2.145] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis 2020;70:2355-65. [PMID: 31513710 DOI: 10.1093/cid/ciz696] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
98 Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Journal of Hepatology 2019;70:33-9. [DOI: 10.1016/j.jhep.2018.09.030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
99 McNaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. J Gen Virol 2020;101:271-83. [PMID: 32134374 DOI: 10.1099/jgv.0.001387] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
100 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
101 Wan Y, Zheng Z, Liu R, Zhu Z, Zhou H, Zhang X, Boumaraf S. A Multi-Scale and Multi-Level Fusion Approach for Deep Learning-Based Liver Lesion Diagnosis in Magnetic Resonance Images with Visual Explanation. Life (Basel) 2021;11:582. [PMID: 34207262 DOI: 10.3390/life11060582] [Reference Citation Analysis]
102 Ahmed S, Ullah N, Parveen S, Javed I, Jalil NAC, Murtey MD, Sheikh IS, Khan S, Ojha SC, Chen K, Xiao J. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/9199190] [Reference Citation Analysis]
103 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Reference Citation Analysis]
104 Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol 2020;165:1633-9. [PMID: 32356185 DOI: 10.1007/s00705-020-04639-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
105 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
106 Hernandez Sampere L, Vermehren J, Mücke VT, Graf C, Peiffer KH, Dultz G, Zeuzem S, Waidmann O, Filmann N, Bojunga J, Sarrazin C, Friedrich-Rust M, Mücke MM. Point Shear-Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver-Related Events in Patients With Chronic Viral Hepatitis. Hepatol Commun 2021;5:112-21. [PMID: 33437905 DOI: 10.1002/hep4.1623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc 2019;22 Suppl 6:e25348. [PMID: 31468692 DOI: 10.1002/jia2.25348] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
108 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Grebely J, Dore GJ, Alami NN, Conway B, Dillon JF, Gschwantler M, Felizarta F, Hézode C, Tomasiewicz K, Fredrick LM, Dumas EO, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. Int J Drug Policy 2019;66:73-9. [PMID: 30735896 DOI: 10.1016/j.drugpo.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
110 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
111 Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, Attia D. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319-323. [PMID: 31758735 DOI: 10.1111/liv.14308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
112 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
113 Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Can J Gastroenterol Hepatol 2019;2019:4029541. [PMID: 30941326 DOI: 10.1155/2019/4029541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
114 Gioula G, Sinakos E, Gigi E, Goulis I, Vasiliadis T, Minti F, Akriviadis E. 'Distribution of Hepatitis C Virus genotypes in northern Greece in the last decade: descriptive analysis and clinical correlations'. Glob Health Epidemiol Genom 2019;4:e5. [PMID: 31516719 DOI: 10.1017/gheg.2019.4] [Reference Citation Analysis]
115 Mancinelli CR, Rossi N, Capra R. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Ther Clin Risk Manag 2021;17:765-76. [PMID: 34354358 DOI: 10.2147/TCRM.S282390] [Reference Citation Analysis]
116 Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ, Marra F. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat 2019;26:951-60. [PMID: 30977945 DOI: 10.1111/jvh.13110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
117 Cink RD, Lukin KA, Bishop RD, Zhao G, Pelc MJ, Towne TB, Gates BD, Ravn MM, Hill DR, Ding C, Cullen SC, Mei J, Leanna MR, Henle J, Napolitano JG, Nere NK, Chen S, Sheikh A, Kallemeyn JM. Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis. Org Process Res Dev 2020;24:183-200. [DOI: 10.1021/acs.oprd.9b00469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
118 Gómez-Ayerbe C, Palacios R, Ríos MJ, Téllez F, Sayago C, Martín-Aspas A, Camacho A, Muñoz L, Santos J; HEPAVIR Group. Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic? Int J STD AIDS 2021;:9564624211033756. [PMID: 34293985 DOI: 10.1177/09564624211033756] [Reference Citation Analysis]
119 Oe N, Takeda H, Eso Y, Takai A, Marusawa H. Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication. Pathogens 2022;11:430. [DOI: 10.3390/pathogens11040430] [Reference Citation Analysis]
120 Lampejo T. Sofosbuvir in the treatment of hepatitis E virus infection: a review of in vitro and in vivo evidence. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.02.003] [Reference Citation Analysis]
121 Cammarota S, Citarella A, Guida A, Conti V, Iannaccone T, Flacco ME, Bravi F, Naccarato C, Piscitelli A, Piscitelli R, Valente A, Calella G, Coppola N, Parruti G. The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study). PLoS One 2019;14:e0219396. [PMID: 31291351 DOI: 10.1371/journal.pone.0219396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
122 Tapp H, Ludden T, Shade L, Thomas J, Mohanan S, Leonard M. Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system. Prev Med Rep 2020;17:101036. [PMID: 31970042 DOI: 10.1016/j.pmedr.2019.101036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Choi IS, Kim KM, Shim SG. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study. Arab J Gastroenterol 2021;22:23-7. [PMID: 33223391 DOI: 10.1016/j.ajg.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Velosa J, Macedo G. Elimination of Hepatitis C in Portugal: An Urban Legend? GE Port J Gastroenterol 2020;27:166-71. [PMID: 32509922 DOI: 10.1159/000505582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Calleja JL, Macias J, Forns X, Garcia F, Berenguer M, Garcia Deltoro M, Buti M, Granados R, Carrion JA, Morano L, Fernandez I, Coste P, Pineda JA. Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol 2018;41:597-608. [PMID: 30270150 DOI: 10.1016/j.gastrohep.2018.07.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
126 Teengam P, Nisab N, Chuaypen N, Tangkijvanich P, Vilaivan T, Chailapakul O. Fluorescent paper-based DNA sensor using pyrrolidinyl peptide nucleic acids for hepatitis C virus detection. Biosens Bioelectron 2021;189:113381. [PMID: 34090155 DOI: 10.1016/j.bios.2021.113381] [Reference Citation Analysis]
127 Ragan K, Pandya A, Holotnak T, Koger K, Collins N, Swain MG. Hepatitis C Virus Screening of High-Risk Patients in a Canadian Emergency Department. Can J Gastroenterol Hepatol 2020;2020:5258289. [PMID: 32211349 DOI: 10.1155/2020/5258289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Pijnenburg DWM, van Seyen M, Abbink EJ, Colbers A, Drenth JPH, Burger DM. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. J Antimicrob Chemother 2020;75:2661-5. [PMID: 32544221 DOI: 10.1093/jac/dkaa230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Li J, Wu DB, Jiang W, Chen XB, Xiao GB, Wang YH, Wang ML, Tao YC, Chen EQ. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Medicine (Baltimore) 2020;99:e22726. [PMID: 33120769 DOI: 10.1097/MD.0000000000022726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS One 2020;15:e0233446. [PMID: 32433676 DOI: 10.1371/journal.pone.0233446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Indolfi G, Ricci S. Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block. Hepatol Commun 2018;2:1289-92. [PMID: 30411074 DOI: 10.1002/hep4.1261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, Sauer AP, Awad T, Christensen PB. Incidence, prevalence and risk factors for hepatitis C in Danish prisons. PLoS One 2019;14:e0220297. [PMID: 31348813 DOI: 10.1371/journal.pone.0220297] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
134 Manso CF, Bibby DF, Lythgow K, Mohamed H, Myers R, Williams D, Piorkowska R, Chan YT, Bowden R, Ansari MA, Ip CLC, Barnes E, Bradshaw D, Mbisa JL. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front Microbiol 2020;11:576572. [PMID: 33162957 DOI: 10.3389/fmicb.2020.576572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
135 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
136 Durcan E, Hatemi I, Sonsuz A, Canbakan B, Ozdemir S, Tuncer M. The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:246-50. [PMID: 31441798 DOI: 10.1097/MEG.0000000000001501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
137 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
138 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
139 Coghlan M, O'Leary A, Melanophy G, Bergin C, Norris S. Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort. Int J Clin Pharm 2019;41:1227-38. [PMID: 31297695 DOI: 10.1007/s11096-019-00876-6] [Reference Citation Analysis]
140 Kannan A, Biswas L, Kumar A, Kurian J, S Nair A, Suresh P, Sadasivan S, Biswas R. Improving Diagnosis of Hepatitis C Virus Infection Using Hepatitis C Core Antigen Testing in a Resource-Poor Setting. Rev Soc Bras Med Trop 2021;54:e02532020. [PMID: 33605377 DOI: 10.1590/0037-8682-0253-2020] [Reference Citation Analysis]
141 Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, Dan YY, Huang CC, Lai CL, Tanwandee T, Teo BW, Wong GL, Yeoh EK, Iseki K, Leung CB, Park HC, Kanjanabuch T, Lu W, Fung J, Jia J, Kanda E, Law MC, Liu H, Loo CK, Mak SK, Lui SL, Tang HL, Wang AY, Yu ML, Cheung M, Jadoul M. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney Int Rep 2020;5:1129-38. [PMID: 32775812 DOI: 10.1016/j.ekir.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
142 Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O. Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. J Viral Hepat 2021;28:1177-89. [PMID: 34003542 DOI: 10.1111/jvh.13545] [Reference Citation Analysis]
143 Warkad SD, Nimse SB, Song KS, Kim T. Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes. ACS Omega 2020;5:10794-9. [PMID: 32455199 DOI: 10.1021/acsomega.0c00386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. mBio 2020;11:e00172-20. [PMID: 32234812 DOI: 10.1128/mBio.00172-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
145 Ingiliz P, Tacke F. How effective and how durable is DAA-therapy in HCV-infected drug users? Liver Int 2019;39:2238-9. [PMID: 31777171 DOI: 10.1111/liv.14284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, Gheorghe L, Ryder S, Kondili LA. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver Int 2021;41:934-48. [PMID: 33529499 DOI: 10.1111/liv.14808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
147 Abdullatif HM, Ramzi R, Mogahed EA, Ghobrial CM, El Rasheed Abd El Zaher BA, El Raziky MS, El-Karaksy HM. Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Clin Drug Investig 2019;39:857-64. [PMID: 31240576 DOI: 10.1007/s40261-019-00805-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). Intern Emerg Med 2018;13:1139-66. [PMID: 30255464 DOI: 10.1007/s11739-018-1940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clin Infect Dis 2021;72:1392-400. [PMID: 32166305 DOI: 10.1093/cid/ciaa253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
150 Ponti ML, Comitini F, Murgia D, Ganga R, Canu R, Dessì C, Foschini ML, Leoni G, Morittu M, Perra M, Pilia MP, Casini MR, Zappu A, Origa R. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major. Dig Liver Dis 2019;51:561-7. [PMID: 30658940 DOI: 10.1016/j.dld.2018.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
151 Kuntzen C, Bagha Z. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.012] [Reference Citation Analysis]
152 Virzì A, Roca Suarez AA, Lupberger J. Interferon revisited: Peering behind the lines of antiviral defense. J Hepatol 2020;73:496-8. [PMID: 32660730 DOI: 10.1016/j.jhep.2020.05.032] [Reference Citation Analysis]
153 Chouikha A, Ghrabi A, Ghodbane A, Hammemi W, Khedhiri M, Sadraoui A, Touzi H, Hassine HB, Maatoug S, Bensaoud C, Abdelhak S, Bouarrouj S, Gdoura M, Chaouachi H, Triki H. Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal. Front Microbiol 2021;12:697859. [PMID: 34385988 DOI: 10.3389/fmicb.2021.697859] [Reference Citation Analysis]
154 Xue W, Liu K, Qiu K, Shen Y, Pan Z, Hu P, Peng M, Chen M, Ren H. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation? Int J Infect Dis 2019;83:56-63. [PMID: 30959250 DOI: 10.1016/j.ijid.2019.03.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
155 Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo A, Sanai F, Derbala MF, Örmeci N, Dalekos GN, Al-Busafi S, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk M, Marzouk S, Toyoda H. Development and multicenter validation of FIB-6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C. Hepatol Res 2021. [PMID: 34767312 DOI: 10.1111/hepr.13729] [Reference Citation Analysis]
156 Minami T, Tateishi R, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T, Arai M, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, Koike K. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer 2021;10:309-19. [PMID: 34414119 DOI: 10.1159/000513705] [Reference Citation Analysis]
157 Smith DA, Bradshaw D, Mbisa JL, Manso CF, Bibby DF, Singer JB, Thomson EC, da Silva Filipe A, Aranday-Cortes E, Ansari MA, Brown A, Hudson E, Benselin J, Healy B, Troke P, McLauchlan J, Barnes E, Irving WL. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. J Viral Hepat 2021;28:1256-64. [PMID: 34003556 DOI: 10.1111/jvh.13549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Fernández de Cañete Camacho JC, Mancebo Martínez A, García Mena MA, Moreno Planas JM. Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs. Gastroenterol Hepatol 2021:S0210-5705(21)00251-X. [PMID: 34543719 DOI: 10.1016/j.gastrohep.2021.09.003] [Reference Citation Analysis]
159 Fallatah HI, Al-Dabbagh A, Hiejazi MT, Hanbazazah SAA, Hussein AO, Al-Sahafi MA, Akbar HO. Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. Saudi J Med Med Sci 2020;8:118-24. [PMID: 32587493 DOI: 10.4103/sjmms.sjmms_272_19] [Reference Citation Analysis]
160 Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B. Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infect Dis 2020;7:ofaa040. [PMID: 32104719 DOI: 10.1093/ofid/ofaa040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
161 Chromy D, Mandorfer M, Bucsics T, Schwabl P, Bauer D, Scheiner B, Schmidbauer C, Lang GF, Szekeres T, Ferenci P, Trauner M, Reiberger T. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. AIDS Patient Care STDS 2019;33:197-206. [PMID: 31067123 DOI: 10.1089/apc.2018.0333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
162 Yen YH, Kuo FY, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice. Medicine (Baltimore) 2019;98:e16270. [PMID: 31277150 DOI: 10.1097/MD.0000000000016270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
163 Smith DA, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J, McLauchlan J, Foster GR, Irving WL, Simmonds P, Pedergnana V, Ramirez S, Bukh J, Barnes E, Ansari MA; STOP-HCV Consortium. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nat Commun 2021;12:6105. [PMID: 34671027 DOI: 10.1038/s41467-021-25649-6] [Reference Citation Analysis]
164 Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal 2021;35:e23755. [PMID: 33788295 DOI: 10.1002/jcla.23755] [Reference Citation Analysis]
165 Torti C, Scaglione V, Cesana BM, Costa C, Marascio N, Schiaroli E, Busti C, Bastianelli S, Mazzitelli M, Trecarichi EM, Francisci D. Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. Health Sci Rep 2021;4:e273. [PMID: 33969232 DOI: 10.1002/hsr2.273] [Reference Citation Analysis]
166 Düzenli T, Köseoğlu H. Physician awareness of hepatitis C virus among different departments. Clin Exp Hepatol 2020;6:354-8. [PMID: 33511284 DOI: 10.5114/ceh.2020.102155] [Reference Citation Analysis]
167 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
168 Sánchez-Azofra M, Fernández I, García-Buey ML, Domínguez-Domínguez L, Fernández-Rodríguez CM, Mancebo A, Bonet L, Ryan P, Gea F, Díaz-Sánchez A, García-Mayor M, Martín-Carbonero L, Castillo P, Manzano ML, González-Moreno L, Pulido F, Gutiérrez ML, Moreno JM, García-Amengual IM, Cuevas G, Guerrero A, Rivero-Fernández M, Portales ME, Montes ML, Olveira A. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals. Liver Int 2021;41:2885-91. [PMID: 34392590 DOI: 10.1111/liv.15032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Taneja S, Duseja A, Mehta M, De A, Verma N, Premkumar M, Dhiman RK, Singh V, Singh MP, Ratho RK, Ramachandran R, Kumar V, Kohli HS. Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021;41:705-709. [PMID: 33025685 DOI: 10.1111/liv.14685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
170 Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. J Viral Hepat 2021;28:728-38. [PMID: 33555102 DOI: 10.1111/jvh.13479] [Reference Citation Analysis]
171 Huang W, Wang M, Gong Q, Yu D, Chen P, Lin J, Han Y, Su Y, Qu L, Zhang X. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. Microb Drug Resist. 2019;. [PMID: 30702389 DOI: 10.1089/mdr.2018.0360] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
172 Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
173 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
174 Sastre L, To-Figueras J, Lens S, Rodriguez-Tajes S, Bartres C, Aguilera P, Badenas C, Oliva R, Pocurull A, Forns X, Mariño Z. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther 2020;51:968-73. [PMID: 32294804 DOI: 10.1111/apt.15703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
175 Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, Postel N, Friedrich-Rust M, Hofmann WP; German Hepatitis C-Registry. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. J Viral Hepat 2020;27:690-8. [PMID: 32096310 DOI: 10.1111/jvh.13280] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
176 Yen YH, Kee KM, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One 2019;14:e0208858. [PMID: 30625158 DOI: 10.1371/journal.pone.0208858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Chen KY, Ko YM, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. J Gastroenterol Hepatol 2020;35:151-6. [PMID: 31373037 DOI: 10.1111/jgh.14815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
178 Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int 2020;40:539-48. [PMID: 31241820 DOI: 10.1111/liv.14186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
179 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, Liang PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Chuang WL, Yu ML. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36:920-928. [PMID: 32643842 DOI: 10.1002/kjm2.12275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
181 Hanafy AS, Soliman S, Abd-Elsalam S. Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma. Hepatol Res 2019;49:377-84. [PMID: 30570817 DOI: 10.1111/hepr.13303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
182 Corma-gómez A, Macías J, Téllez F, Freyre-carrillo C, Morano L, Rivero-juárez A, Ríos MJ, Alados JC, Vera-méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. Clinical Infectious Diseases 2019. [DOI: 10.1093/cid/ciz1140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
183 Wang JH. Application of Ultrasound Liver Elastography to the Diagnosis and Monitoring of Liver Disease. J Med Ultrasound 2019;27:1-2. [PMID: 31031528 DOI: 10.4103/JMU.JMU_108_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
184 Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol 2019;70:15-23. [PMID: 30266283 DOI: 10.1016/j.jhep.2018.09.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
185 Chevaliez S, Pawlotsky J. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. Journal of Hepatology 2018;69:916-26. [DOI: 10.1016/j.jhep.2018.05.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
186 Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, Ward Z, Vickerman P, Hickman M, Dillon JF. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat 2019;26:519-28. [PMID: 30422370 DOI: 10.1111/jvh.13035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
187 Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Reference Citation Analysis]
188 Ranjbar Kermani F, Mousavi Hosseini K, Amini-kafiabad S, Maghsudlu M, Sharifi Z, Mansournia MA. Phylogenetic Analysis of NS5B Region of Hepatitis C Genotype 3a Virus among Different Risk Groups in Iran. Hepat Mon 2021;20. [DOI: 10.5812/hepatmon.108936] [Reference Citation Analysis]
189 Sarwar S, Tarique S, Aleem A, Khan AA. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol 2019;31:1035-9. [PMID: 31274596 DOI: 10.1097/MEG.0000000000001376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
190 Huang H, Tang H, Deng H, Shen J, Zhou Q, Xie W, Wu J, Chen J. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients. Transpl Infect Dis 2019;21:e13018. [PMID: 30369001 DOI: 10.1111/tid.13018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
191 Lin SF, Tung SY, Wei KL, Chen CH, Hu TH, Shen CH, Chang TS, Chen WM, Yen CW, Wang JH, Hung CH, Lu SN. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C. PLoS One 2020;15:e0229994. [PMID: 32126125 DOI: 10.1371/journal.pone.0229994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Caspi DD, Cink RD, Clyne D, Diwan M, Engstrom KM, Grieme T, Mei J, Miller RW, Mitchell C, Napolitano JG, Nere N, Ravn MM, Sheikh A, Wagaw S, Zhang H. Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV. Tetrahedron 2019;75:4271-86. [DOI: 10.1016/j.tet.2019.05.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
193 Moradifard S, Sharifi Z, Arabkhazaeli A, Ghasemi F. Evaluating serum levels of miR-181a and miR-let7a in HCV infected Iranian patients compared with healthy individuals. Gene Reports 2021;22:101001. [DOI: 10.1016/j.genrep.2020.101001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Ferreira GSA, Watanabe ALC, Trevizoli NC, Jorge FMF, Diaz LGG, Araujo MCCL, Araujo GC, Machado AC. Leukocytoclastic vasculitis caused by hepatitis C virus in a liver transplant recipient: A case report. World J Hepatol 2019;11:402-8. [PMID: 31114644 DOI: 10.4254/wjh.v11.i4.402] [Reference Citation Analysis]
195 Folch C, Saludes V, Reyes-Ureña J, Antuori A, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants. Int J Drug Policy 2021;90:103057. [PMID: 33310634 DOI: 10.1016/j.drugpo.2020.103057] [Reference Citation Analysis]
196 Chiu WN, Hung CH, Lu SN, Chen MY, Tung SY, Wei KL, Lu CK, Chen CH, Hu TH, Hu JH, Chen WM, Chang TS. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. J Viral Hepat 2020;27:866-72. [PMID: 32343472 DOI: 10.1111/jvh.13305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
197 Yosef T, Ibrahim WA, El-ghandour A, Attia S, El-nakeep S. Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00075-8] [Reference Citation Analysis]
198 Piecha F, Gänßler JM, Ozga AK, Wehmeyer MH, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse AW, Schulze Zur Wiesch J. Treatment and re-treatment results of HCV patients in the DAA era. PLoS One 2020;15:e0232773. [PMID: 32369527 DOI: 10.1371/journal.pone.0232773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
199 Ohlendorf V, Maasoumy B. Renal function in HCV therapy: Just another thing to ignore? Liver Int 2020;40:1018-20. [DOI: 10.1111/liv.14391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Minemura M, Tajiri K, Hayashi Y, Takahashi N, Watanabe K, Hanaoka T, Araki Y, Takahashi K, Takahara T, Kojima S, Yasuda I. Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. Intern Med 2021;60:3239-43. [PMID: 33896867 DOI: 10.2169/internalmedicine.7132-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Schwarzkopf R, Novikov D, Anoushiravani AA, Feng JE, Vigdorchik J, Schurko B, Dwyer MK, Bedair HS. The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty. Bone Joint J 2019;101-B:667-74. [PMID: 31154838 DOI: 10.1302/0301-620X.101B6.BJJ-2018-0723.R3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
202 Rinaldi L, Messina V, Di Marco V, Iovinella V, Claar E, Cariti G, Sacco R, De Luca M, Scifo G, Gatti P, Barbarini G, Pace Palitti V, Quartini M, Tundo P, D'Offizi G, Parruti G, di Rosolini MA, Garrucciu G, Cosco L, Benanti F, Gimignani G, Vespasiani Gentilucci U, Di Lorenzo F, D'Antò M, Nevola R, Lupia T, Rosato V, Morbiducci V, Luzzitelli I, Sozio F, Di Stefano M, Ciraci E, Bulla F, Guarisco R, Cangiano C, Imparato M, Maggi P, Ascione A, Craxì A, Izzi A. Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. Am J Gastroenterol 2021;116:1248-55. [PMID: 34074828 DOI: 10.14309/ajg.0000000000001147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
204 Chamorro-de-Vega E, Rodríguez-González CG, Giménez-Manzorro Á, Herranz A, Sanjurjo M. Hepatitis C virus infection and the role of a pharmaceutical care program. Am J Health Syst Pharm 2020;77:479-86. [PMID: 31811290 DOI: 10.1093/ajhp/zxz266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
205 Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C, Antonelli M, Sestito L, Rando MM, Tosoni A, De Cosmo S, Gasbarrini A, Addolorato G. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry 2018;9:474. [PMID: 30327620 DOI: 10.3389/fpsyt.2018.00474] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
206 Ridruejo E, Piñero F, Mendizabal M, Cheinquer H, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Zuain MGV, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, Araujo A, Varón A, Silva M; Latin American Liver Research Educational and Awareness Network (LALREAN). Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort. J Med Virol 2020;92:3545-55. [DOI: 10.1002/jmv.26383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Asselah T, Shafran SD, Bourgeois S, Lai CL, Mathurin P, Willems B, Nguyen MH, Davis MN, Huang KC, Svarovskaia E, Osinusi A, McNally J, Brainard DM, Shaikh OS, Tran TT. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. J Viral Hepat. 2019;26:1229-1232. [PMID: 31216086 DOI: 10.1111/jvh.13159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Caudai C, Papalini C, Francisci D, Baldelli F, Zazzi M. Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA). Journal of Antimicrobial Chemotherapy 2020;75:252-3. [DOI: 10.1093/jac/dkz402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
209 Agarwal K, Brown SE. Achieving Cure From Hepatitis C Virus Is Good for More Than Just the Liver Graft. Liver Transpl 2018;24:997-8. [PMID: 30028069 DOI: 10.1002/lt.25298] [Reference Citation Analysis]
210 Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, Conway B, Jackson D, Asselah T, Gschwantler M, Tomasiewicz K, Aguilar H, Asatryan A, Hu Y, Mensa FJ. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend 2019;194:487-94. [PMID: 30529905 DOI: 10.1016/j.drugalcdep.2018.11.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
211 Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J. Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clin Infect Dis 2020;70:2369-76. [PMID: 31300820 DOI: 10.1093/cid/ciz633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
212 Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend 2020;206:107705. [PMID: 31718924 DOI: 10.1016/j.drugalcdep.2019.107705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
213 D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2021:S0168-8278(21)02043-2. [PMID: 34592366 DOI: 10.1016/j.jhep.2021.09.013] [Reference Citation Analysis]
214 Li Y, Zhao L, Geng N, Zhu W, Liu H, Bai H. Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data. Virol J 2020;17:36. [PMID: 32178702 DOI: 10.1186/s12985-020-01316-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Pérez AB, Chueca N, García-deltoro M, Martínez-sapiña AM, Lara-pérez MM, García-bujalance S, Aldámiz-echevarría T, Vera-méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-arboledas JC, Poyato A, Téllez F, Rivero-juárez A, Merino D, Vivancos-gallego MJ, Rosales-zábal JM, García F, Ocete MD, Simón MÁ, Rincón P, Reus S, De la Iglesia A, García-arata I, Jiménez M, Jiménez F, Hernández-quero J, Galera C, Balghata MO, Primo J, Masiá M, Espinosa N, Delgado M, von-Wichmann MÁ, Collado A, Santos J, Mínguez C, Díaz-flores F, Fernández E, Bernal E, De Juan J, Antón JJ, Vélez M, Aguilera A, Navarro D, Arenas JI, Fernández C, Espinosa MD, Ríos MJ, Alonso R, Hidalgo C, Hernández R, Téllez MJ, Rodríguez FJ, Antequera P, Delgado C, Martín P, Crespo J, Becerril B, Pérez Ó, García-herola A, Montero J, Freyre C, Grau C. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. Journal of Hepatology 2019;71:876-88. [DOI: 10.1016/j.jhep.2019.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
216 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
217 Lazarus JV, Pericàs JM, Elsharkawy AM. Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO. Liver Int 2018;38:1902-5. [PMID: 30358061 DOI: 10.1111/liv.13944] [Reference Citation Analysis]
218 Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 2020;14:225-38. [PMID: 32128704 DOI: 10.1007/s12072-020-10019-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
219 Antuori A, Montoya V, Piñeyro D, Sumoy L, Joy J, Krajden M, González-Gómez S, Folch C, Casabona J, Matas L, Colom J, Saludes V, Martró E; HepCdetect II Study Group. Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots. Hepatology 2021;74:591-606. [PMID: 33609288 DOI: 10.1002/hep.31757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
220 Mücke MM, Herrmann E, Mücke VT, Graf C, Zeuzem S, Vermehren J. Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis. Liver Int 2019;39:1652-60. [PMID: 31033122 DOI: 10.1111/liv.14126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
221 Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol 2019; 25(40): 6094-6106 [PMID: 31686765 DOI: 10.3748/wjg.v25.i40.6094] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
222 Qi M, Yang M, Xu L, Ma C, Huang P, Sun J, Shi J, Hu Y. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res 2021;296:198354. [PMID: 33639223 DOI: 10.1016/j.virusres.2021.198354] [Reference Citation Analysis]
223 Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020;3:e2021173. [PMID: 33206188 DOI: 10.1001/jamanetworkopen.2020.21173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Eshetu A, Hauser A, Schmidt D, Bartmeyer B, Bremer V, Obermeier M, Ehret R, Volkwein A, Bock CT, Bannert N. Comparison of two immunoassays for concurrent detection of HCV antigen and antibodies among HIV/HCV co-infected patients in dried serum/plasma spots. J Virol Methods 2020;279:113839. [PMID: 32087189 DOI: 10.1016/j.jviromet.2020.113839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00467-2] [Reference Citation Analysis]
226 Lee WJ, Jones M, Wing PAC, Rajagopal S, Foster GR. The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation. Cell Mol Gastroenterol Hepatol 2021;11:1163-75. [PMID: 33248325 DOI: 10.1016/j.jcmgh.2020.11.012] [Reference Citation Analysis]
227 Ledesma F, Buti M, Domínguez-Hernández R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. Rev Esp Quimioter 2020;33:240-8. [PMID: 32510188 DOI: 10.37201/req/030.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
228 Huang R, Rao H, Xie Q, Gao Z, Li W, Jiang D, Mo H, Massetto B, Stamm LM, Brainard DM, Wei L. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol 2019;91:1313-8. [PMID: 30861150 DOI: 10.1002/jmv.25454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
229 Kumar R, Chan KP, Ekstrom VSM, Wong JCC, Lim KL, Ng WC, Woo SM, Chan KS, Thangaraju S, Kee TYS, Gan SSW, Foo MWY, Oon LLE, Chow WC. Hepatitis C virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts. J Med Virol 2021;93:3738-43. [PMID: 32797627 DOI: 10.1002/jmv.26433] [Reference Citation Analysis]
230 Saif-Al-Islam M, Abdelaal UM, Younis MA, Alghany Algahlan HA, Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. Gastroenterol Res Pract 2021;2021:8811203. [PMID: 34122539 DOI: 10.1155/2021/8811203] [Reference Citation Analysis]
231 Higley C, Hsu CC, Smith C, Nadella S, Lalos AT. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports. World J Hepatol 2020; 12(12): 1341-1348 [PMID: 33442459 DOI: 10.4254/wjh.v12.i12.1341] [Reference Citation Analysis]
232 Blach S, Sanai FM. HCV Burden and Barriers to Elimination in the Middle East. Clin Liver Dis (Hoboken). 2019;14:224-227. [PMID: 32015874 DOI: 10.1002/cld.897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Cheng P, Chen C, Yu M, Lin C, Lin C, Peng C, Tseng K, Lo C, Tseng I, Liu C. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. Journal of Microbiology, Immunology and Infection 2021;54:588-95. [DOI: 10.1016/j.jmii.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
234 Mohammed BS, Aidoo M. Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines? Int J Hepatol 2020;2020:9750194. [PMID: 32550025 DOI: 10.1155/2020/9750194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 D'ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of Hepatology 2019;70:379-87. [DOI: 10.1016/j.jhep.2018.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 23.3] [Reference Citation Analysis]
236 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Degasperi E, Galmozzi E, Facchetti F, Farina E, D'Ambrosio R, Soffredini R, Iavarone M, Lampertico P. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. J Viral Hepat 2019;26:1233-6. [PMID: 31177595 DOI: 10.1111/jvh.13155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
238 Tronina O, Durlik M, Orłowska I, Lorenc B, Łapiński TW, Garlicki A, Dybowska D, Zarębska-Michaluk D, Tudrujek-Zdunek M, Citko J, Janczewska E, Kaczmarczyk M, Jaroszewicz J, Krygier R, Klapaczyński J, Dobracka B, Białkowska-Warzecha J, Piekarska A, Simon K, Halota W, Pawłowska M, Tomasiewicz K, Flisiak R. Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. Ann Gastroenterol 2021;34:438-46. [PMID: 33948071 DOI: 10.20524/aog.2021.0595] [Reference Citation Analysis]
239 Abu Freha N, Wainstock T, Menachem TN, Sheiner E. Maternal Hepatitis B Virus or Hepatitis C Virus Carrier Status and Long-Term Endocrine Morbidity of the Offspring-A Population-Based Cohort Study. J Clin Med 2020;9:E796. [PMID: 32183302 DOI: 10.3390/jcm9030796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Pericàs JM, Bromberg DJ, Ocampo D, Schatz E, Wawer I, Wysocki P, Safreed-Harmon K, Lazarus JV. Hepatitis C services at harm reduction centres in the European Union: a 28-country survey. Harm Reduct J 2019;16:20. [PMID: 30898122 DOI: 10.1186/s12954-019-0290-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
241 Chiu HC, Chiu YC, Yang EH, Chang TT, Chien SC, Wu IC, Wu CH, Cheng PN. Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. J Formos Med Assoc 2021;120:983-90. [PMID: 32891488 DOI: 10.1016/j.jfma.2020.08.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Reference Citation Analysis]
243 Cengiz M, Ozenirler S. Serum Peptidyl-prolyl Cis-trans Isomerase NIMA-interacted 1 (Pin1) as a Non-invasive Marker for Liver Fibrosis due to Chronic Hepatitis C Virus. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.116687] [Reference Citation Analysis]
244 Tinti F, Mitterhofer AP, Umbro I, Nightingale P, Inston N, Ghallab M, Ferguson J, Mirza DF, Ball S, Lipkin G, Muiesan P, Perera MTPR. Combined liver-kidney transplantation versus liver transplant alone based on KDIGO stratification of estimated glomerular filtration rate: data from the United Kingdom Transplant registry - a retrospective cohort study. Transpl Int 2019;32:918-32. [PMID: 30793378 DOI: 10.1111/tri.13413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
245 Negro F. Expanded benefits of curing the extrahepatic manifestations of HCV infection. Gut 2018;67:1917-9. [PMID: 29871969 DOI: 10.1136/gutjnl-2018-316578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
246 Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int 2020;40:758-68. [PMID: 31710759 DOI: 10.1111/liv.14295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
247 Crespo J, Llerena S, Cobo C, Cabezas J, Cuadrado A. HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front? Curr Hepatology Rep 2019;18:259-67. [DOI: 10.1007/s11901-019-00472-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
248 Hakim MS, Rahmadika N, Jariah ROA. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. Rev Med Virol 2019;30. [DOI: 10.1002/rmv.2094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
249 Nesterova E, Tanaschuk E, Abdurakhmanov D, Gemdzhian E, Kravchenko S, Mangasarova Y, Krasilnikova I, Bagova M. Safe and effective treatment of follicular lymphoma in patients with HCV ‐infection. Hematological Oncology 2020;38:604-6. [DOI: 10.1002/hon.2751] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
250 Cannella R, Vernuccio F, Celsa C, Cabibbo G, Calvaruso V, Greco S, Battaglia S, Choudhury KR, Tang A, Midiri M, Di Marco V, Cammà C, Brancatelli G. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver Int 2021;41:2179-88. [PMID: 33908147 DOI: 10.1111/liv.14914] [Reference Citation Analysis]
251 Wang Q, Chang B, Li X, Zou Z. Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis. J Clin Transl Hepatol 2021;9:90-8. [PMID: 33604259 DOI: 10.14218/JCTH.2020.00104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
253 Arora A, Kumar A, Prasad N, Duseja A, Acharya SK, Agarwal SK, Aggarwal R, Anand AC, Bhalla AK, Choudhary NS, Chawla YK, Dhiman RK, Dixit VK, Gopalakrishnan N, Gupta A, Hegde UN, Jasuja S, Jha V, Kher V, Kumar A, Madan K, Maiwall R, Mathur RP, Nayak SL, Pandey G, Pandey R, Puri P, Rai RR, Raju SB, Rana DS, Rao PN, Rathi M, Saraswat VA, Saxena S, Shalimar, Sharma P, Singh SP, Singal AK, Soin AS, Taneja S, Varughese S. INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 2021;11:354-86. [PMID: 33994718 DOI: 10.1016/j.jceh.2020.09.005] [Reference Citation Analysis]
254 Llaneras J, Riveiro-Barciela M, Rando-Segura A, Marcos-Fosch C, Roade L, Velázquez F, Rodríguez-Frías F, Esteban R, Buti M. Etiologies and Features of Acute Viral Hepatitis in Spain. Clin Gastroenterol Hepatol 2021;19:1030-7. [PMID: 32663522 DOI: 10.1016/j.cgh.2020.07.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. J Viral Hepat 2021;28:1190-9. [PMID: 33896097 DOI: 10.1111/jvh.13523] [Reference Citation Analysis]
256 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
257 Proeschold-Bell RJ, Evon DM, Yao J, Niedzwiecki D, Makarushka C, Keefe KA, Patkar AA, Mannelli P, Garbutt JC, Wong JB, Wilder JM, Datta SK, Hodge T, Naggie S, Fried MW, Muir AJ. A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. Hepatology 2020;71:1894-909. [PMID: 31803945 DOI: 10.1002/hep.31058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
258 Aragri M, Milana M, Di Maio VC, Lenci I, Carioti L, Perno CF, Svicher V, Angelico M, Ceccherini-Silberstein F. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Clin Microbiol Infect 2020;26:1266-8. [PMID: 32240711 DOI: 10.1016/j.cmi.2020.03.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res 2021;51:51-61. [PMID: 33021009 DOI: 10.1111/hepr.13576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
261 Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs 2020;38:202-10. [PMID: 31701431 DOI: 10.1007/s10637-019-00870-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
262 Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int. 2020;19:541-546. [PMID: 32660841 DOI: 10.1016/j.hbpd.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
263 Colapietro F, Aghemo A. Do gamma-glutamyltransferase levels identify HCV patients who require lifelong post-SVR follow-up? Liver Int 2020;40:509-10. [PMID: 32124542 DOI: 10.1111/liv.14394] [Reference Citation Analysis]
264 Rockstroh JK. Noninvasive Markers for Monitoring Fibrosis Regression After Hepatitis C Virus Cure: What Do They Promise? Clin Infect Dis 2021;73:478-9. [PMID: 32503039 DOI: 10.1093/cid/ciaa698] [Reference Citation Analysis]
265 Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831-8. [PMID: 30879789 DOI: 10.1016/j.jhep.2018.12.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
266 Wei J, Mei Y, Li J, Yuan J, Yang X, Xu Z, Lin G, Zhang J, Zhao Z, Zhang X. Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection. Liver Research 2020;4:101-7. [DOI: 10.1016/j.livres.2020.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Bulankina AV, Richter RM, Welsch C. Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. Pathogens 2022;11:102. [DOI: 10.3390/pathogens11010102] [Reference Citation Analysis]
268 Schauer C, van Rijnsoever M, Gane E. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. J Viral Hepat 2019;26:1372-6. [PMID: 31323163 DOI: 10.1111/jvh.13179] [Reference Citation Analysis]
269 Elliott T, Cooke GS, Garvey L. Interventions to reduce acute hepatitis C virus in HIV-positive MSM. Curr Opin Infect Dis 2020;33:1-9. [PMID: 31789696 DOI: 10.1097/QCO.0000000000000614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Bray M, Andrei G, Ballana E, Carter K, Durantel D, Gentry B, Janeba Z, Moffat J, Oomen CJ, Tarbet B, Riveira-Muñoz E, Esté JA; International Society for Antiviral Research. Meeting report: 31st International Conference on Antiviral Research. Antiviral Res 2018;158:88-102. [PMID: 30086336 DOI: 10.1016/j.antiviral.2018.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
271 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
272 Calvaruso V, Bruix J. Towards personalized screening for hepatocellular carcinoma: Still not there. J Hepatol. 2020;73:1319-1321. [PMID: 32771323 DOI: 10.1016/j.jhep.2020.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
273 Tseng CW, Wu SF, Chen CY, Ho YC, He YT, Tseng KC. Characteristics of regulatory T-cell function in patients with chronic hepatitis B and C coinfection. J Viral Hepat 2020;27:800-9. [PMID: 32243022 DOI: 10.1111/jvh.13298] [Reference Citation Analysis]
274 Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology 2020;72:1924-34. [PMID: 33022803 DOI: 10.1002/hep.31588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
275 Dasgupta S, Imamura M, Gorstein E, Nakahara T, Tsuge M, Churkin A, Yardeni D, Etzion O, Uprichard SL, Barash D, Cotler SJ, Dahari H, Chayama K. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. J Infect Dis 2020;222:1165-9. [PMID: 32363394 DOI: 10.1093/infdis/jiaa219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
276 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Nevola R, Rinaldi L, Zeni L, Romano C, Marrone A, Galiero R, Pafundi PC, Acierno C, Vetrano E, Adinolfi LE. Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2021;15:643-56. [PMID: 33445990 DOI: 10.1080/17474124.2021.1877136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
278 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
279 Chen W, Fu M, Zhang C, Xing Q, Zhou F, Lin M, Dong X, Huang J, Lin S, Hong M, Zheng Q, Pan J. Deep Learning-Based Universal Expert-Level Recognizing Pathological Images of Hepatocellular Carcinoma and Beyond. Front Med 2022;9:853261. [DOI: 10.3389/fmed.2022.853261] [Reference Citation Analysis]
280 Martin MT, Patel S, Kulik L, Chan C. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. Journal of Hepatology 2021;75:251-4. [DOI: 10.1016/j.jhep.2021.02.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
281 Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477-487. [PMID: 30982721 DOI: 10.1016/s2468-1253(19)30046-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 17.7] [Reference Citation Analysis]
282 Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ANRS CO13 Hepavih study Group. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J Hepatol 2018; 10(11): 856-866 [PMID: 30533186 DOI: 10.4254/wjh.v10.i11.856] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
283 Llovet LP, Gratacós-Ginés J, Ortiz O, Rodriguez-Tajes S, Lens S, Reverter E, Ruiz-Ortiz E, Costa J, Viñas O, Forns X, Parés A, Londoño MC. Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. Liver Int 2020;40:558-64. [PMID: 31863722 DOI: 10.1111/liv.14332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
284 Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology 2019;69:513-23. [PMID: 30125371 DOI: 10.1002/hep.30225] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
285 González-Corvillo C, Beneyto I, Sánchez-Fructuoso A, Perelló M, Alonso A, Mazuecos A, Jiménez C, Zárraga S, Paul J, Lauzurica R, Hernández D, Guirado L, Franco A, Ruiz JC, Llorente S, Crespo M, Rodríguez-Benot A, de Gracia Guindo MDC, Díaz-Corte C, Gentil MÁ. Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study. Transplant Direct 2019;5:e510. [PMID: 32095505 DOI: 10.1097/TXD.0000000000000954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
286 Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Aichelburg MC, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United European Gastroenterol J 2019;7:507-16. [PMID: 31065368 DOI: 10.1177/2050640619835394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
287 Perales C. Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance. Int J Antimicrob Agents 2020;56:105562. [PMID: 30315919 DOI: 10.1016/j.ijantimicag.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
288 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
289 Boerekamps A, Vanwolleghem T, van der Valk M, van den Berk GE, van Kasteren M, Posthouwer D, Dofferhoff ASM, van Hoek B, Ramsoekh D, Koopsen J, Schinkel J, Florence E, Arends JE, Rijnders BJ. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol 2019;70:554-7. [PMID: 30527953 DOI: 10.1016/j.jhep.2018.10.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
290 Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat 2019;26:685-96. [PMID: 30739368 DOI: 10.1111/jvh.13080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
291 Pascut D, Cavalletto L, Pratama MY, Bresolin S, Trentin L, Basso G, Bedogni G, Tiribelli C, Chemello L. Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers (Basel) 2019;11:E1773. [PMID: 31717959 DOI: 10.3390/cancers11111773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
292 Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Chen C, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Chang TS, Huang J, Yang C, Hu J, Lin C, Chen C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Mo L, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Liu C, Dai C, Chuang W, Lin H, Kao J, Yu M. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.012] [Reference Citation Analysis]
293 Bal T, Onlen Y, Babayigit C, Yumer Y, Sahin SI. The impact of hepatitis C viremia status on lung functions in chronic hepatitis c patients. Afr Health Sci 2019;19:1988-92. [PMID: 31656481 DOI: 10.4314/ahs.v19i2.21] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Ridruejo E, Cheinquer H, Marciano S, Mendizabal M, Piñero F, Wolff FH, de Araujo A, Coelho Borges S, Kliemann D, Fleck A, de Maman Í Jr, Nader LA, Garrastazul P, Bermúdez C, Haddad L, Gadano A, Silva M. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. J Viral Hepat 2019;26:1200-9. [PMID: 31141239 DOI: 10.1111/jvh.13148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
295 Saludes V, Antuori A, Reinhardt B, Viciana I, Clavijo E, Schreiber L, Tenenbaum M, Rodriguez-Frias F, Quer J, Matas L, Martró E. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. Sci Rep 2019;9:3678. [PMID: 30842623 DOI: 10.1038/s41598-019-40099-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
296 Jachs M, Binter T, Chromy D, Schalk H, Pichler K, Bauer D, Simbrunner B, Hartl L, Schmidbauer C, Mayer F, Strassl R, Mandorfer M, Gschwantler M, Reiberger T. Outcomes of an HCV elimination program targeting the Viennese MSM population. Wien Klin Wochenschr 2021;133:635-40. [PMID: 34181068 DOI: 10.1007/s00508-021-01898-9] [Reference Citation Analysis]
297 Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. Hepatol Res 2020;50:426-38. [DOI: 10.1111/hepr.13467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
298 Persico M, Masarone M, Aglitti A, Armenante C, Giordano A, Guardiola A, Raimondi G, Contaldi C, Nigro C, Marena G, De Luna A. HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. Liver Int. 2019;39:1845-1851. [PMID: 31169953 DOI: 10.1111/liv.14166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
299 Isfordink CJ, Brakenhoff SM, van Dijk M, van der Valk M, de Knegt RJ, Arends JE, Drenth JP; HepNed study group. Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C. BMJ Open Gastroenterol 2020;7:e000396. [PMID: 32377367 DOI: 10.1136/bmjgast-2020-000396] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
300 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
301 Lee JS, Choi HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. J Gastroenterol Hepatol 2021. [PMID: 33788314 DOI: 10.1111/jgh.15514] [Reference Citation Analysis]
302 Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E2013. [PMID: 30223539 DOI: 10.3390/ijerph15092013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
303 Olmos-Martínez JM, Hernández JL, Fábrega E, Olmos JM, Crespo J, González-Macías J. Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection. Arch Osteoporos 2020;15:72. [PMID: 32399944 DOI: 10.1007/s11657-020-00752-1] [Reference Citation Analysis]
304 Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One 2018;13:e0206947. [PMID: 30403744 DOI: 10.1371/journal.pone.0206947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Pisaturo M, Russo A, Onorato L, Coppola N. Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis. Acta Biomed 2019;90:187-96. [PMID: 31124995 DOI: 10.23750/abm.v90i2.8374] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
306 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
307 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
308 Margusino-Framiñán L, Bobadilla-Pérez E, Cid-Silva P, Rodríguez-Sotelo A, Yáñez-Rubal JC, Mena-de-Cea Á, Suárez-López F, Prieto-Pérez A, Giménez-Arufe V, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice. J Med Virol 2020. [PMID: 32181917 DOI: 10.1002/jmv.25772] [Reference Citation Analysis]
309 Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118:556-64. [PMID: 30527566 DOI: 10.1016/j.jfma.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
310 Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019;35:161-170. [PMID: 31367613 DOI: 10.1159/000500963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
311 Zarębska-Michaluk D. Viral hepatitis C treatment shortening - what is the limit? Clin Exp Hepatol 2019;5:265-70. [PMID: 31893236 DOI: 10.5114/ceh.2019.88085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
312 Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol 2020;86:132-42. [PMID: 31656054 DOI: 10.1111/bcp.14148] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Lee JJ, Wei YJ, Lin MY, Niu SW, Hsu PY, Huang JC, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Huang CF, Chiu YW, Chuang WL, Yu ML. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. PLoS One 2020;15:e0242601. [PMID: 33216807 DOI: 10.1371/journal.pone.0242601] [Reference Citation Analysis]
314 Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70:1019-1023. [PMID: 30857780 DOI: 10.1016/j.jhep.2019.01.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
315 Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
316 Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans? Clin Mol Hepatol 2018;24:294-6. [PMID: 30200750 DOI: 10.3350/cmh.2018.1009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
317 Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
318 Alison D Marshall A, Anna Conway A, Cunningham EB, Valerio H, Silk D, Alavi M, Wade A, Lam T, Zohrab K, Dunlop A, Connelly C, Christmass M, Cock V, Burns C, Henderson C, Wiseman V, Dore GJ, Grebely J. Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment. Drug and Alcohol Dependence 2022. [DOI: 10.1016/j.drugalcdep.2022.109438] [Reference Citation Analysis]
319 Metwally K, Elsabaawy M, Abdel-Samiee M, Morad W, Ehsan N, Abdelsameea E. FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clin Exp Hepatol 2020;6:335-8. [PMID: 33511281 DOI: 10.5114/ceh.2020.102157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
320 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
322 Sakamori R, Yamada R, Shinkai K, Doi A, Tahata Y, Shigekawa M, Kodama T, Hikita H, Yamada T, Tatsumi T, Takehara T. Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis. Intern Med 2021;60:745-50. [PMID: 33642562 DOI: 10.2169/internalmedicine.6029-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Crespo J, Lázaro P, Blasco AJ, Aguilera A, García-Samaniego J, Eiros JM, Calleja JL, García F. Hepatitis C reflex testing in Spain in 2019: A story of success. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:119-26. [PMID: 32451150 DOI: 10.1016/j.eimc.2020.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
324 Fourati S, Rodriguez C, Soulier A, Donati F, Hamadat S, Poiteau L, Demontant V, Brillet R, Ahnou N, Gricourt G, Chevaliez S, Ahmed-Belkacem A, Pawlotsky JM. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Aliment Pharmacol Ther 2020;52:1583-91. [PMID: 32886807 DOI: 10.1111/apt.16054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
325 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A–E. Adv Ther. [DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
326 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
327 Basharkhah S, Sabet F, Ghezeldasht SA, Mosavat A, Jahantigh HR, Barati E, Shamsian K, Saleh-Moghaddam M, Sharebyani H, Hassannia T, Shamsian SAA. Prediction of HCV load using genotype, liver biomarkers, and clinical symptoms by a mathematical model in patients with HCV infection. Microbiol Immunol 2019;63:449-57. [PMID: 31373399 DOI: 10.1111/1348-0421.12735] [Reference Citation Analysis]
328 Wong XZ, Amirah A, Gan CC, Fatiha S, Maznah D, Yahya R, Ganapathy S, Tan SS, Mohamed R, Lim SK. Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. Nephrology (Carlton) 2021;26:463-70. [PMID: 33580732 DOI: 10.1111/nep.13862] [Reference Citation Analysis]
329 Nsanzimana S, Penkunas MJ, Liu CY, Sebuhoro D, Ngwije A, Remera E, Umutesi J, Ntirenganya C, Mugeni SD, Serumondo J. Effectiveness of Direct-Acting Antivirals for the treatment of chronic hepatitis C in Rwanda: A retrospective study. Clin Infect Dis 2020:ciaa701. [PMID: 32505127 DOI: 10.1093/cid/ciaa701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
330 Lin YC, Li SW, Ku SY, Hsieh HT, Lin MH, Chang SY, Wu WW, Sun NL, Cheng SH, Cheng CY. Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial. Infect Drug Resist 2019;12:937-45. [PMID: 31114268 DOI: 10.2147/IDR.S206938] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
331 Li YR, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. World J Gastroenterol 2021; 27(31): 5181-5188 [PMID: 34497443 DOI: 10.3748/wjg.v27.i31.5181] [Reference Citation Analysis]
332 Amer F, Yousif MM, Hammad NM, Garcia-Cehic D, Gregori J, Rando-Segura A, Nieto-Aponte L, Esteban JI, Rodriguez-Frias F, Quer J. Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. Infect Drug Resist 2019;12:2799-807. [PMID: 31571936 DOI: 10.2147/IDR.S214735] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
333 Su F, Ioannou GN. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Curr Hepatol Rep 2018;17:377-84. [PMID: 30923667 DOI: 10.1007/s11901-018-0424-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
334 Cowan EA, Dinani A, Brandspiegel S, O'Brien-Lambert C, Zaheer J, Eiting E, Loo G, Calderon Y. Nontargeted Hepatitis C Screening in an Urban Emergency Department in New York City. J Emerg Med 2021;60:299-309. [PMID: 33213988 DOI: 10.1016/j.jemermed.2020.09.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat 2019;26:1266-75. [PMID: 31278795 DOI: 10.1111/jvh.13170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
336 Calvaruso V, Petta S, Ferraro D, La Mantia C, Gibilaro G, Reina G, Di Maio VC, Licata A, Ceccherini-Silberstein F, Di Marco V, Craxì A. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. Dig Liver Dis 2021:S1590-8658(21)00776-3. [PMID: 34593348 DOI: 10.1016/j.dld.2021.09.007] [Reference Citation Analysis]
337 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 Zarębska‐michaluk D, Jaroszewicz J, Pabjan P, Łapiński TW, Mazur W, Krygier R, Dybowska D, Halota W, Pawłowska M, Janczewska E, Buczyńska I, Simon K, Dobracka B, Citko J, Laurans Ł, Tudrujek‐zdunek M, Tomasiewicz K, Piekarska A, Sitko M, Białkowska‐warzecha J, Klapaczyński J, Sobala‐szczygieł B, Horban A, Berak H, Deroń Z, Lorenc B, Socha Ł, Tronina O, Flisiak R. Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real‐world experience? Journal of Gastroenterology and Hepatology 2021;36:1944-52. [DOI: 10.1111/jgh.15337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
339 Mücke MM, Maasoumy B, Dietz J, Mücke VT, Simon CO, Canchola JA, Cornberg M, Marins EG, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C, Vermehren J. Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. PLoS One 2019;14:e0224751. [PMID: 31738773 DOI: 10.1371/journal.pone.0224751] [Reference Citation Analysis]
340 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Kowalik-Mikołajewska B, Marczyńska M. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klin Padiatr 2020. [PMID: 33339066 DOI: 10.1055/a-1304-3542] [Reference Citation Analysis]
341 Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis 2021;73:468-77. [PMID: 32504083 DOI: 10.1093/cid/ciaa702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
342 Asker B, Jawad R, Asreah R, Jamal H, Jassem A, Inaya MA, Baker HA, Kozma S, Mansour E, McNamara B, Miller R, Darlington O, McEwan P, Sugrue DM, Jarallah H. Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment. Pharmacoeconomics 2021. [PMID: 34396494 DOI: 10.1007/s40273-021-01064-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
344 Stasi C, Sadalla S, Carradori E, Monti M, Petraccia L, Madia F, Gragnani L, Zignego AL. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. Curr Med Res Opin 2020;36:245-9. [PMID: 31702411 DOI: 10.1080/03007995.2019.1691517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
345 Parlati L, Pol S. HCV-infected dialysis patients: History is changing. Clin Res Hepatol Gastroenterol 2019;43:225-7. [PMID: 30616879 DOI: 10.1016/j.clinre.2018.12.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
346 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
347 Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69:293-300. [PMID: 29551706 DOI: 10.1016/j.jhep.2018.03.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 21.8] [Reference Citation Analysis]
348 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
349 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
350 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Reference Citation Analysis]
351 Merchante N, Mena Á, Pascasio JM, Marco A, Rodriguez M, Hernandez-Guerra M, Simón MA. Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection. Medicine (Baltimore) 2021;100:e27838. [PMID: 34797315 DOI: 10.1097/MD.0000000000027838] [Reference Citation Analysis]
352 Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019;54:1042-50. [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
353 Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol. 2019;13:839-848. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
354 Jang TY, Liang PC, Liu TW, Wei YJ, Yeh ML, Hsu CT, Hsu PY, Lin YH, Hsieh MH, Huang CI, Huang CF, Lin ZY, Chen SC, Huang JF, Dai CY, Yu ML, Chuang WL. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. J Chin Med Assoc 2021;84:255-60. [PMID: 33433134 DOI: 10.1097/JCMA.0000000000000478] [Reference Citation Analysis]
355 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
356 Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic Signaling Induced by HCV Infection. Viruses 2018;10:E538. [PMID: 30279347 DOI: 10.3390/v10100538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
357 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
358 Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G, Guarneri C. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomedicines 2022;10:228. [DOI: 10.3390/biomedicines10020228] [Reference Citation Analysis]
359 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Reference Citation Analysis]
360 Fujita N, Nishie A, Asayama Y, Ishigami K, Nakayama T, Ushijima Y, Kakihara D, Takayama Y, Morita K, Ishimatsu K, Takao S, Yoshizumi T, Furusyo N, Honda H. Increased and More Heterogeneous Gadoxetic Acid Uptake of the Liver Parenchyma after Hepatitis C Virus Eradication by Direct Antiviral Agent. Magn Reson Med Sci 2020;19:389-93. [PMID: 32051362 DOI: 10.2463/mrms.tn.2019-0183] [Reference Citation Analysis]
361 Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol 2020;72:472-80. [PMID: 31629779 DOI: 10.1016/j.jhep.2019.10.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
362 Minme R, Holzmann I, Tovo CV, Almeida PRL. PROFILE OF PATIENTS WITH CHRONIC HEPATITIS C IN A PUBLIC HEALTH PROGRAM IN SOUTHERN BRAZIL. Arq Gastroenterol 2018;55:403-6. [PMID: 30785526 DOI: 10.1590/S0004-2803.201800000-86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol 2021;36:2247-54. [PMID: 33624849 DOI: 10.1111/jgh.15469] [Reference Citation Analysis]
364 Busschots D, Kremer C, Koc ÖM, Heyens L, Bielen R, Apers L, Florence E, Messiaen P, Van Laethem K, Van Wijngaerden E, Nevens F, Hens N, Robaeys G. The hepatitis C cascade of care in the Belgian HIV population: One step closer to elimination. Int J Infect Dis 2021;105:217-23. [PMID: 33610786 DOI: 10.1016/j.ijid.2021.02.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
365 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
366 Allaire M, Gilgenkrantz H. The aged liver: Beyond cellular senescence. Clin Res Hepatol Gastroenterol 2020;44:6-11. [PMID: 31427197 DOI: 10.1016/j.clinre.2019.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
367 Comarmond C, Cacoub P, Saadoun D. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol. 2020;13:1756284820942617. [PMID: 32782479 DOI: 10.1177/1756284820942617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
368 D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, Messina E, Fanetti I, Puoti M, Aghemo A, Viganò P, Vinci M, Menzaghi B, Lombardi A, Pan A, Pigozzi MG, Grossi P, Lazzaroni S, Spinelli O, Invernizzi P, Maggiolo F, Terreni N, Monforte AD, Poggio PD, Taddei MT, Colombo S, Pozzoni P, Molteni C, Brocchieri A, Bhoori S, Buscarini E, Centenaro R, Mendeni M, Colombo AE, Di Marco M, Dionigi E, Bella D, Borghi M, Zuin M, Zaltron S, Noventa F, Annalisa S, Lampertico P, Fagiuoli S. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Dig Liver Dis 2020;52:190-8. [PMID: 31813755 DOI: 10.1016/j.dld.2019.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
369 Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
370 Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoove M, Thompson AJ. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis 2020:ciaa1318. [PMID: 32887983 DOI: 10.1093/cid/ciaa1318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
371 Jalota A, Lindner BK, Thomas B, Lerma EV. Hepatitis C and Treatment in Patients with Chronic Kidney Disease. Dis Mon 2021;67:101017. [PMID: 32553421 DOI: 10.1016/j.disamonth.2020.101017] [Reference Citation Analysis]
372 Bhattacharjee C, Singh M, Das D, Chaudhuri S, Mukhopadhyay A. Current therapeutics against HCV. Virusdisease 2021;:1-16. [PMID: 34307769 DOI: 10.1007/s13337-021-00697-0] [Reference Citation Analysis]
373 Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, Cicchetti A. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert Rev Pharmacoecon Outcomes Res 2019;19:363-74. [PMID: 30351994 DOI: 10.1080/14737167.2019.1537784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J 2019;7:642-50. [PMID: 31210942 DOI: 10.1177/2050640619840149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
375 Giuffrè M, Fouraki S, Campigotto M, Colombo A, Visintin A, Buonocore MR, Aversano A, Budel M, Tinè F, Abazia C, Masutti F, Crocè LS. Alanine aminotransferase and spleno-portal dynamics affect spleen stiffness measured by point shear-wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis. J Ultrasound 2021;24:67-73. [PMID: 32304009 DOI: 10.1007/s40477-020-00456-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
376 Ross PE, Young JR, O'Connor CM, Anoushiravani AA, DiCaprio MR. Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty. JBJS Rev 2021;9. [PMID: 34757978 DOI: 10.2106/JBJS.RVW.20.00223] [Reference Citation Analysis]
377 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
378 Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infect Dis Ther 2021;10:269-80. [PMID: 33141401 DOI: 10.1007/s40121-020-00364-9] [Reference Citation Analysis]
379 Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, Cela M, Copetti M, Losappio R. SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS One 2019;14:e0215783. [PMID: 31091254 DOI: 10.1371/journal.pone.0215783] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
380 Li CF, Tsao SM, Liao HH, Chen SC, Lee YT. Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e22435. [PMID: 33019424 DOI: 10.1097/MD.0000000000022435] [Reference Citation Analysis]
381 Liu CH, Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. J Formos Med Assoc 2020;119:1871-5. [PMID: 32553687 DOI: 10.1016/j.jfma.2020.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Roncero C, Villegas JL, Martínez-Rebollar M, Buti M. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol 2018;11:999-1030. [PMID: 30199279 DOI: 10.1080/17512433.2018.1519392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
383 Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int 2018;38:1906-10. [PMID: 30022590 DOI: 10.1111/liv.13932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
384 Nguyen D, Smith D, Vaughan-jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology 2020;73:794-9. [DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
385 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
386 Bischoff J, Rockstroh JK. Are there any challenges left in hepatitis C virus therapy of HIV-infected patients? International Journal of Antimicrobial Agents 2020;56:105527. [DOI: 10.1016/j.ijantimicag.2018.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
387 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
388 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
389 Ioannou GN, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology. 2019;156:446-460.e2. [PMID: 30367836 DOI: 10.1053/j.gastro.2018.10.033] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
390 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
391 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
392 Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis 2020;296:40-7. [DOI: 10.1016/j.atherosclerosis.2020.01.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
393 Wu DB, Jiang W, Wang YH, Chen B, Wang ML, Tao YC, Chen EQ, Tang H. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. J Viral Hepat 2019;26:316-22. [PMID: 30380166 DOI: 10.1111/jvh.13033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
394 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
395 Sandmann L, Manns MP, Maasoumy B. Utility of viral kinetics in HCV therapy - It is not over until it is over? Liver Int 2019;39:815-7. [PMID: 31020775 DOI: 10.1111/liv.14047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
396 Guo M, Lu J, Gan T, Xiang X, Xu Y, Xie Q, Zhong J. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. Antiviral Res 2019;171:104612. [PMID: 31542377 DOI: 10.1016/j.antiviral.2019.104612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
397 Ridruejo E, Soza A. Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030? Clin Liver Dis (Hoboken) 2019;13:43-5. [PMID: 31139354 DOI: 10.1002/cld.771] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
398 Gitto S, Vizzutti F, Schepis F, Turco L, Aspite S, Vitale G, Arena U, Villa E, Laffi G, Debernardi-Venon W, Fanelli F, Andreone P, Marra F; DAA-TIPS group. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. Dig Liver Dis 2019;51:870-4. [PMID: 30824409 DOI: 10.1016/j.dld.2018.11.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
399 Ramachandran J, Budd S, Slattery H, Muller K, Mohan T, Cowain T, Tilley E, Baas A, Wigg L, Alexander J, Woodman R, Kaambwa B, Wigg A. Hepatitis C virus infection in Australian psychiatric inpatients: A multicenter study of seroprevalence, risk factors and treatment experience. J Viral Hepat 2019;26:609-12. [DOI: 10.1111/jvh.13056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
400 Tosetti G, Degasperi E, Farina E, D'Ambrosio R, Soffredini R, Borghi M, La Mura V, Primignani M, Lampertico P. Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy. Am J Gastroenterol 2021;116:1342-4. [PMID: 33606382 DOI: 10.14309/ajg.0000000000001158] [Reference Citation Analysis]
401 Aghemo A, Valenti L, Viganò M, Masetti C, Rumi MG, Prati D. Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood? Lancet Haematol 2021;8:e8-e10. [PMID: 33357486 DOI: 10.1016/S2352-3026(20)30402-6] [Reference Citation Analysis]
402 Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis 2020;222:S758-72. [PMID: 33245354 DOI: 10.1093/infdis/jiaa366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
403 Nicolini LA, Menzaghi B, Molteni C, Vichi F, Cascio A, Parisini A, De Socio GV, Falasca K, Bonfanti P, Di Biagio A. Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C". J Med Virol 2022;94:436-8. [PMID: 34499359 DOI: 10.1002/jmv.27329] [Reference Citation Analysis]
404 Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. J Gastroenterol Hepatol 2021. [PMID: 34618379 DOI: 10.1111/jgh.15703] [Reference Citation Analysis]
405 Kaposi PN, Unger Z, Fejér B, Kucsa A, Tóth A, Folhoffer A, Szalay F, Bérczi V. Interobserver agreement and diagnostic accuracy of shearwave elastography for the staging of hepatitis C virus-associated liver fibrosis. J Clin Ultrasound 2020;48:67-74. [PMID: 31463955 DOI: 10.1002/jcu.22771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
406 Huang JF, Huang CF, Yeh ML, Dai CY, Yu ML, Chuang WL. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? Expert Rev Anti Infect Ther. 2018;16:907-912. [PMID: 30396303 DOI: 10.1080/14787210.2018.1544492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
407 Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S, Akarca US; Early Access Program (EAP) Study Groupa. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. J Viral Hepat 2019;26:666-74. [PMID: 30740820 DOI: 10.1111/jvh.13075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
408 Catlett B, Lamoury FMJ, Bajis S, Hajarizadeh B, Martinez D, Mowat Y, Cunningham PH, Jacka BP, Cloherty GA, Marks P, Dore GJ, Grebely J, Applegate TL. Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. J Viral Hepat 2019;26:1423-30. [PMID: 31448470 DOI: 10.1111/jvh.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
409 Ridruejo E, Soza YA. ¿Qué estrategias deben implementarse en Latinoamérica para erradicar el virus de la hepatitis C antes de 2030? Clin Liver Dis (Hoboken) 2019;13:S9-S11. [PMID: 31333822 DOI: 10.1002/cld.838] [Reference Citation Analysis]
410 Fernández-Caso B, Fernández-Caballero JÁ, Chueca N, Rojo E, de Salazar A, García Buey L, Cardeñoso L, García F. Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing. Sci Rep 2019;9:9264. [PMID: 31239457 DOI: 10.1038/s41598-019-42605-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
411 Gómez L, Reygosa C, Morales-arráez DE, Ramos R, Pérez A, Hernández A, Quintero E, Gutiérrez F, Diaz-flores F, Hernández-guerra M. Evaluación de la precisión diagnóstica del sistema Cobas 6800 para la detección de los niveles de viremia del virus de la hepatitis C a partir de muestras de gotas de sangre seca en papel de filtro. Enfermedades Infecciosas y Microbiología Clínica 2020;38:267-74. [DOI: 10.1016/j.eimc.2019.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
413 Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int 2020;40:1853-9. [PMID: 32383275 DOI: 10.1111/liv.14502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
414 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
415 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
416 Girometti N, Devitt E, Phillips J, Nelson M, Whitlock G. High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection. J Viral Hepat 2019;26:627-34. [PMID: 30661272 DOI: 10.1111/jvh.13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
417 Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen HY, Wang HW, Huang GT, Peng CY. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol 2019;19:63. [PMID: 31029101 DOI: 10.1186/s12876-019-0973-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
418 De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, Burlone ME, Minisini R, Pirisi M. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:4216451. [PMID: 32382265 DOI: 10.1155/2020/4216451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
419 Klimova EA, Burnevich EZ, Chulanov VP, Gusev DA, Znoyko OO, Batskikh SN, Kizlo SN, Mamonova NA, Tarkhova EP, Krasavina EN, Samsonov MY, Yushchuk ND. [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. Ter Arkh 2019;91:67-74. [PMID: 32598756 DOI: 10.26442/00403660.2019.08.000384] [Reference Citation Analysis]
420 Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69:1178-1187. [PMID: 30006068 DOI: 10.1016/j.jhep.2018.07.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
421 Ing Lorenzini K, Girardin F. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients. Liver Int 2019;40:32-44. [DOI: 10.1111/liv.14283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
422 Levander XA, Vega TA, Seaman A, Korthuis PT, Englander H. Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs. Int J Drug Policy 2021;:103356. [PMID: 34226111 DOI: 10.1016/j.drugpo.2021.103356] [Reference Citation Analysis]
423 Yousif MM, Ahmed H, Elsadek HM, Shendi AM, Gouda TM, Elsayed IA, Gendia MA, Magdy MM, Lbrahim NF, Sadek AMEM, Zaki AM, Shafeik H, Zahran MH. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. J Viral Hepat 2020;27:1190-201. [PMID: 32564500 DOI: 10.1111/jvh.13349] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Kilany S, Ata L, Gomaa A, Sabry A, Nada A, Tharwa ES, Badra G, Abogabal A, Elwaraky M, Moaz E, Ezzat S, Elsharawy A, Waked I. Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. J Hepatocell Carcinoma 2021;8:925-35. [PMID: 34408991 DOI: 10.2147/JHC.S295330] [Reference Citation Analysis]
425 Pawlotsky J, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis 2020;40:392-402. [DOI: 10.1055/s-0040-1713657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
426 Vallejo A, Moldes LM, Trigo M, Ordoñez P, Rodriguez-Otero L, Cabrera JJ, Gude MJ, Navarro D, Cañizares A, García-Campello M, Agulla A, Aguilera A; en nombre del Grupo de Estudio del DUSP en Galicia. Generalized implementation of reflex testing of hepatitis C in Galicia: Results for reflection. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00025-2. [PMID: 33632540 DOI: 10.1016/j.eimc.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Simpson H, Manley P, Lawler J, Morey S, Buchanan E, Hewett M, Knowles J, Miller C, McCarron B, Valappil M, McPherson S. Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. J Public Health (Oxf) 2019;41:700-6. [PMID: 30351415 DOI: 10.1093/pubmed/fdy190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
428 Awan AA, Jadoul M, Martin P. Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline. Clin Gastroenterol Hepatol 2020;18:2158-67. [PMID: 31376491 DOI: 10.1016/j.cgh.2019.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
429 Sacco R, Messina V, Gentilucci UV, Adinolfi LE, Ascione A, Barbarini G, Barlattani A, Cariti G, Cozzolongo R, Fimiani B, Francavilla R, Furlan C, Garrucciu G, Iovinella V, Rinaldi L, Marignani M, Begini P, Palitti VP, Pellicelli AM, Scifo G, Facciorusso A, Giacomelli L, Shah A, Bertino G, Perazzo S, Bresci G, Izzi A. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study. Drugs Context 2020;9:2020-4-11. [PMID: 33408749 DOI: 10.7573/dic.2020-4-11] [Reference Citation Analysis]
430 de Gennaro N, Diella L, Monno L, Angarano G, Milella M, Saracino A. Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. BMC Infect Dis 2020;20:196. [PMID: 32138757 DOI: 10.1186/s12879-020-4922-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
431 Shahid I, Alzahrani AR, Al-Ghamdi SS, Alanazi IM, Rehman S, Hassan S. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics (Basel) 2021;11:1253. [PMID: 34359335 DOI: 10.3390/diagnostics11071253] [Reference Citation Analysis]
432 Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN)., Italian Association for the Study of the Liver (AISF)., Italian Society of Infectious and Tropical Disease (SIMIT)., Italian Society of Internal Medicine (SIMI). Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). J Nephrol 2018;31:685-712. [PMID: 30255440 DOI: 10.1007/s40620-018-0523-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
433 de Torres Santos AP, Martins Silva VC, Mendes-Corrêa MC, Lemos MF, de Mello Malta F, Santana RAF, Dastoli GTF, de Castro VFD, Pinho JRR, Moreira RC. Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. Infect Drug Resist 2021;14:723-30. [PMID: 33658809 DOI: 10.2147/IDR.S247071] [Reference Citation Analysis]
434 Hirsch CB, Pereira MFB, Benevides GN, Bernardes TM, Palandri GG, Bastos KLM, Toma RK, de Azevedo RA, Marques HHS. Hepatitis C in Children and Adolescents of a Brazilian Tertiary Center: Identifying Patients Eligible for Direct-Acting Antivirals. Pediatr Infect Dis J 2020;39:e276-8. [PMID: 32496409 DOI: 10.1097/INF.0000000000002725] [Reference Citation Analysis]
435 Romagnoli D. Elimination of hepatitis C virus infection in Europe: targeting the obstacles. Exploration of Medicine. [DOI: 10.37349/emed.2022.00075] [Reference Citation Analysis]
436 Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment Pharmacol Ther 2020;52:168-81. [PMID: 32441382 DOI: 10.1111/apt.15780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
437 Garbuzenko DV. [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Vopr Virusol 2021;66:331-9. [PMID: 34738448 DOI: 10.36233/0507-4088-70] [Reference Citation Analysis]
438 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 15.3] [Reference Citation Analysis]
439 Gallego I, Soria ME, Gregori J, de Ávila AI, García-Crespo C, Moreno E, Gadea I, Esteban J, Fernández-Roblas R, Esteban JI, Gómez J, Quer J, Domingo E, Perales C. Synergistic lethal mutagenesis of hepatitis C virus. Antimicrob Agents Chemother 2019:AAC. [PMID: 31570400 DOI: 10.1128/AAC.01653-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
440 Papadopoulos N, Vasileiadi S, Papavdi M, Sveroni E, Antonakaki P, Dellaporta E, Koutli E, Michalea S, Manolakopoulos S, Koskinas J, Deutsch M. Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography. Ann Gastroenterol 2019;32:498-503. [PMID: 31474797 DOI: 10.20524/aog.2019.0406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
441 Park H, Jiang X, Song HJ, Lo Re V 3rd, Childs-Kean LM, Lo-Ciganic WH, Cook RL, Nelson DR. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. Hepatology 2021;74:566-81. [PMID: 33544904 DOI: 10.1002/hep.31732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Wang JH, Chen CH, Chang CM, Feng WC, Lee CY, Lu SN. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan. J Formos Med Assoc 2020;119:504-8. [PMID: 31350109 DOI: 10.1016/j.jfma.2019.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
443 Butt N, Muhammad I, Abou Bakr A, Akhtar Z, Ali M, Syed Muhammad S, Maheshwary N. Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial. Cureus 2020;12:e6537. [PMID: 32042516 DOI: 10.7759/cureus.6537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
444 Juanbeltz R, Castilla J, Martínez-Baz I, O'Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res 2019;28:1477-84. [PMID: 30666549 DOI: 10.1007/s11136-019-02111-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
445 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
446 Hlaing NKT, Nangia G, Tun KT, Lin S, Maung MZ, Myint KT, Kyaw AMM, Maung ST, Sein Win S, Bwa AH, Loza BL, Win KM, Reddy KR. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. J Viral Hepat 2019;26:1186-99. [PMID: 31104344 DOI: 10.1111/jvh.13133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
447 Ventura-Cots M, Ballester-Ferré MP, Ravi S, Bataller R. Public health policies and alcohol-related liver disease. JHEP Rep 2019;1:403-13. [PMID: 32039391 DOI: 10.1016/j.jhepr.2019.07.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
448 Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML, Peng CY. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol 2021. [PMID: 33963615 DOI: 10.1111/jgh.15538] [Reference Citation Analysis]
449 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Scherz N, Bruggmann P, Brunner N. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment. Int J Drug Policy 2018;62:74-7. [PMID: 30368101 DOI: 10.1016/j.drugpo.2018.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
451 Indolfi G, Fischler B, Gonzalez-Peralta RP, Ciocca M, Porta G, Neelam M, El-Guindi M, Kelly D, Ni YH, Sibal A, Leung DH, Chang MH; Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN). Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2020;70:711-717. [PMID: 32205770 DOI: 10.1097/mpg.0000000000002710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
452 van Seyen M, de Graaff Teulen MJ, van Erp NP, Burger DM. Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MS. Journal of Chromatography B 2019;1110-1111:15-24. [DOI: 10.1016/j.jchromb.2019.01.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
453 Oztürk S, Ağalar C. Updating the Signal-to-cutoff Level to Reduce Anti-hepatitis C Virus False Positivity. Jundishapur J Microbiol 2021;14. [DOI: 10.5812/jjm.119110] [Reference Citation Analysis]
454 Kahn JA. The use of organs from hepatitis C virus-viremic donors into uninfected recipients. Curr Opin Organ Transplant. 2020;25:620-625. [PMID: 33105203 DOI: 10.1097/mot.0000000000000826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, Nielsen M, Isaguliants MG, Mikhailov MI. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 2020;8:E80. [PMID: 32272736 DOI: 10.3390/biomedicines8040080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
456 Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Dig Liver Dis 2019;51:915-21. [PMID: 31031174 DOI: 10.1016/j.dld.2019.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
457 Saludes V, Antuori A, Lazarus JV, Folch C, González-Gómez S, González N, Ibáñez N, Colom J, Matas L, Casabona J, Martró E. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734. [PMID: 32470849 DOI: 10.1016/j.drugpo.2020.102734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
458 Thedja MD, Wibowo DP, El-Khobar KE, Ie SI, Setiawan L, Murti IS, Muljono DH; Turyadi. Improving Linkage to Care of Hepatitis C: Clinical Validation of GeneXpert® HCV Viral Load Point-of-Care Assay in Indonesia. Am J Trop Med Hyg 2021:tpmd201588. [PMID: 33999849 DOI: 10.4269/ajtmh.20-1588] [Reference Citation Analysis]
459 Nangia G, Vierling JM, Kwo P, Brown DD, Klopfer SO, Robertson MN, Haber BA, Reddy KR. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. J Viral Hepat 2020;27:1222-33. [PMID: 32594612 DOI: 10.1111/jvh.13357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
460 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
461 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684 [PMID: 33033572 DOI: 10.4254/wjh.v12.i9.672] [Reference Citation Analysis]
462 Zakalashvili M, Zarkua J, Gish RG, Zhamutashvili M, Sartania V, Weizenegger M, Bartel J, Raabe M, Gvinjilia L, Metreveli S, Barnova M, Abramishvili N, Rtskhiladze I, Metreveli D. Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. Hepatol Res 2021;51:156-65. [PMID: 33207029 DOI: 10.1111/hepr.13587] [Reference Citation Analysis]
463 Kilaru SM, Jacobson IM. Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. Future Virology 2019;14:61-71. [DOI: 10.2217/fvl-2018-0134] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
464 Yamauchi K, Sato M, Osawa L, Matsuda S, Komiyama Y, Nakakuki N, Takada H, Katoh R, Muraoka M, Suzuki Y, Tatsumi A, Miura M, Takano S, Amemiya F, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Maekawa S, Enomoto N. Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing. Hepatol Commun 2022. [PMID: 35357088 DOI: 10.1002/hep4.1929] [Reference Citation Analysis]
465 Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmermann T, Lohmann K, König B, Mauss S. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry. Liver Int 2021;41:949-55. [PMID: 33592123 DOI: 10.1111/liv.14829] [Reference Citation Analysis]
466 Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol 2020;5:940-7. [PMID: 32730785 DOI: 10.1016/S2468-1253(20)30008-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
467 Kc S, Murphy H, Dixit S, Rai A, Pradhan B, Lagrange-Xelot M, Karki N, Dureault A, Karmacharya U, Panthi S, Tulachan N, Kc P, Kc A, Rajbhandari R, Trotter AB, Gölz J, Pradat P, Trépo C, Creac'H P. Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal. PLoS Negl Trop Dis 2020;14:e0008931. [PMID: 33326423 DOI: 10.1371/journal.pntd.0008931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K; KTK49 Liver Study Group. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther 2020;9:851-66. [DOI: 10.1007/s40121-020-00329-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
469 Setiawan VW, Rosen HR. Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis. Hepatology 2020;72:1897-9. [PMID: 33205438 DOI: 10.1002/hep.31639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
470 Turken M, Kose S, Colak Ergun N, Tatar B. Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients. Arab J Gastroenterol 2020;21:278-81. [PMID: 32830089 DOI: 10.1016/j.ajg.2020.08.005] [Reference Citation Analysis]
471 Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Narkewicz MR, Sokal E, Fortuny C, Hsu EK, Del Valle-Segarra A, Zha J, Larsen L, Liu L, Shuster DL, Cohen DE, Rosenthal P. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. Hepatol Commun. 2018;2:1311-1319. [PMID: 30411078 DOI: 10.1002/hep4.1250] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
472 Basso M, Zago D, Pozzetto I, Parisi SG. Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study. European Journal of Gastroenterology & Hepatology 2021;33:e1076-7. [DOI: 10.1097/meg.0000000000002088] [Reference Citation Analysis]
473 El-Khayat H, Kamal EM, Mahmoud H, Gomaa A, Ebeid B, Sameh Y, Hasseb A, El Raziky M, El Serafy M, Doss W, Esmat G, Fouad Y, Attia D. Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens. Eur J Gastroenterol Hepatol 2020;32:440-6. [PMID: 31688311 DOI: 10.1097/MEG.0000000000001581] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson AJ. Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS One 2020;15:e0242101. [PMID: 33206696 DOI: 10.1371/journal.pone.0242101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
475 Piselli P, Serraino D, Fusco M, Girardi E, Pirozzi A, Toffolutti F, Cimaglia C, Taborelli M; Collaborating Study Group. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infect Dis 2021;21:667. [PMID: 34238231 DOI: 10.1186/s12879-021-06336-9] [Reference Citation Analysis]
476 Alimohammadi A, Conway B, Yamamoto L. Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance. BMJ Case Rep 2020;13:e233098. [PMID: 32051160 DOI: 10.1136/bcr-2019-233098] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
477 Sriphoosanaphan S, Thanapirom K, Kerr SJ, Suksawatamnuay S, Thaimai P, Sittisomwong S, Sonsiri K, Srisoonthorn N, Teeratorn N, Tanpowpong N, Chaopathomkul B, Treeprasertsuk S, Poovorawan Y, Komolmit P. Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial. PeerJ 2021;9:e10709. [PMID: 33614272 DOI: 10.7717/peerj.10709] [Reference Citation Analysis]
478 Kang SH, Kim MY. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care. Clin Mol Hepatol 2021;27:100-2. [PMID: 33317234 DOI: 10.3350/cmh.2020.0312] [Reference Citation Analysis]
479 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
480 Sicras Mainar A, Navarro Artieda R, Hernández I, Morillo R. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterol Hepatol 2019;42:465-75. [PMID: 31451229 DOI: 10.1016/j.gastrohep.2019.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
481 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
482 Elhence A, Singh A, Anand A, Kumar R, Ashraf A, Kumar S, Pradhan D, Pathak P, Vaishnav M, Rajput MS, Banyal V, Nayak B, Shalimar. Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C. J Med Virol 2021;93:4982-91. [PMID: 33783006 DOI: 10.1002/jmv.26971] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
483 Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther 2018;7:473-84. [PMID: 30368684 DOI: 10.1007/s40121-018-0218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
484 Tabu K, Mawatari S, Oda K, Kumagai K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Fujisaki K, Imanaka D, Kure T, Taniyama O, Toyodome A, Ijuin S, Sakae H, Sakurai K, Moriuchi A, Kanmura S, Ido A. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. PLoS One 2020;15:e0237475. [PMID: 32790728 DOI: 10.1371/journal.pone.0237475] [Reference Citation Analysis]
485 Kåberg M, Edgren E, Hammarberg A, Weiland O. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity. Scand J Gastroenterol 2019;54:319-27. [PMID: 30907178 DOI: 10.1080/00365521.2019.1580764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
486 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
487 Malandris K, Kalopitas G, Theocharidou E, Germanidis G. The Role of RASs /RVs in the Current Management of HCV. Viruses 2021;13:2096. [PMID: 34696525 DOI: 10.3390/v13102096] [Reference Citation Analysis]
488 Chen CC, Tung SY, Wei KL, Shen CH, Chang TS, Chen WM, Xu HW, Yen CW, Chen YH, Lu SN, Hung CH. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc 2020;119:532-7. [PMID: 31445848 DOI: 10.1016/j.jfma.2019.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
489 Micallef S, Gauci J, Gerada J. Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination. Br J Hosp Med (Lond) 2020;81:1-3. [PMID: 32845753 DOI: 10.12968/hmed.2020.0047] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
490 Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, Chan JMC, Lai KB, Loo CK, Ng ACY, Lai MS, Chan CW, Lau JYL, Fan TTT, Hui AJ, Lam BCY, Cheung WI, Tsang OTY, Lam K, Lai LSW, Luk WF, Li MKK, Lao WC, Lam JTW, Tsang SWC, Kung KN, Chow WH, Tong RKN, Lui TKL, Shan EHS, Yuen MF, Wong VWS. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int 2018;38:1911-9. [PMID: 29981176 DOI: 10.1111/liv.13926] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
491 Nault JC, Nahon P. Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence? Gastroenterology. 2019;156:1558-1560. [PMID: 30926345 DOI: 10.1053/j.gastro.2019.03.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
492 Mendizabal M, Alonso C, Silva MO. Overcoming barriers to hepatitis C elimination. Frontline Gastroenterol 2019;10:207-9. [PMID: 31288259 DOI: 10.1136/flgastro-2018-101114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
493 Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res 2020;174:104694. [PMID: 31857134 DOI: 10.1016/j.antiviral.2019.104694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
494 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
495 Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2021:gutjnl-2020-323663. [PMID: 33741640 DOI: 10.1136/gutjnl-2020-323663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
496 Torrecillas M, Gómez-Muñoz N, Ocete MD, Cuevas PR, Madrid MD, González EO, Cardona CG, García-Deltoro M. One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection. Ann Hepatol 2021;27:100542. [PMID: 34571265 DOI: 10.1016/j.aohep.2021.100542] [Reference Citation Analysis]
497 Muñoz-Hernández R, Ampuero J, Millán R, Gil-Gómez A, Rojas Á, Macher HC, Gallego-Durán R, Gato S, Montero-Vallejo R, Rico MC, Maya-Miles D, Sánchez-Torrijos Y, Soria IC, Stiefel P, Romero-Gómez M. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clin Transl Gastroenterol 2020;11:e00203. [PMID: 32955194 DOI: 10.14309/ctg.0000000000000203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
498 Gastaldi G, Gomes D, Schneiter P, Montet X, Tappy L, Clément S, Negro F. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS One 2019;14:e0217751. [PMID: 31170218 DOI: 10.1371/journal.pone.0217751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
499 Grebely J, Catlett B, Jayasinghe I, Valerio H, Hajarizadeh B, Verich A, Cunningham P, Martinello M, Tillakeratne S, Silk D, Dore GJ, Applegate TL. Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. The Journal of Infectious Diseases 2020;221:2043-9. [DOI: 10.1093/infdis/jiaa037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
500 Liatsos GD. Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19): 5135-5178 [PMID: 34307564 DOI: 10.12998/wjcc.v9.i19.5135] [Reference Citation Analysis]
501 Pugliese N, Giorgini A, Maggi D, Capogreco A, Dibenedetto C, Lubrano Lobianco F, Dal Buono A, Monico S, Meli R, Battezzati PM, Lleo A, De Santis A, Zuin M, Aghemo A. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. Expert Opin Drug Saf 2021;20:839-43. [PMID: 33881366 DOI: 10.1080/14740338.2021.1921144] [Reference Citation Analysis]
502 Lamoury FMJ, Njouom R, Amougou-Atsama M, Yiagnigni Mfopou E, Berishvili N, Sologashvili M, Fajardo E, Malobela A, Macé A, Chirehwa M, Alkhazashvili M, Ivanova Reipold E. Diagnostic Performance and Usability of the Genedrive® HCV ID Kit in Two Decentralized Settings in Cameroon and Georgia. Diagnostics (Basel) 2021;11:746. [PMID: 33921930 DOI: 10.3390/diagnostics11050746] [Reference Citation Analysis]
503 Liu G, Liu F, Xiang HL, Zhang YP, Shi LL, Ye Q, Lv HM, Liang J. Clinical effects of 48 weeks of direct antiviral therapy for chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2022; 30(1): 49-55 [DOI: 10.11569/wcjd.v30.i1.49] [Reference Citation Analysis]
504 Yang X, Ding T, Huang H, Xu Y, Yu J, Chen Z. Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one-step RT-qPCR. Exp Ther Med 2020;20:2284-90. [PMID: 32765706 DOI: 10.3892/etm.2020.8912] [Reference Citation Analysis]
505 Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int 2019;39:2244-60. [PMID: 31125496 DOI: 10.1111/liv.14152] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
506 Kuo MH, Tseng CW, Lee CH, Tseng KC. Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C. Tzu Chi Med J 2020;32:331-8. [PMID: 33163377 DOI: 10.4103/tcmj.tcmj_247_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
507 Grau-López L, Marcos-Fosch C, Daigre C, Palma-Alvarez RF, Rando-Segura A, Llaneras J, Perea-Ortueta M, Rodriguez-Frias F, Martínez-Luna N, Riveiro-Barciela M, Ramos-Quiroga JA, Colom J, Esteban R, Buti M. Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therap Adv Gastroenterol 2021;14:17562848211016563. [PMID: 34471422 DOI: 10.1177/17562848211016563] [Reference Citation Analysis]
508 Na SK, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. J Interferon Cytokine Res. 2019;39:703-710. [PMID: 31216229 DOI: 10.1089/jir.2019.0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
509 Isakov V, Chulanov V, Abdurakhmanov D, Burnevich E, Nurmukhametova E, Kozhevnikova G, Gankina N, Zhuravel S, Romanova S, Hyland RH, Lu S, Svarovskaia ES, McNally J, Brainard DM, Ivashkin V, Morozov V, Bakulin I, Lagging M, Zhdanov K, Weiland O. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. Infect Dis (Lond). 2019;51:131-139. [PMID: 30499360 DOI: 10.1080/23744235.2018.1535186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
510 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the treatment of patients with genotype 3a infection and compensated cirrhosis. J Hepatol 2019;70:562-4. [PMID: 30439391 DOI: 10.1016/j.jhep.2018.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
511 Lau CS, Chen YH, Lim K, de Longueville M, Arendt C, Winthrop K. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. Clin Rheumatol 2021;40:867-75. [PMID: 32740672 DOI: 10.1007/s10067-020-05248-4] [Reference Citation Analysis]
512 Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, Balistreri WF, Bansal S, Jonas MM, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Davison S, Feiterna-Sperling C, Gillis LA, Indolfi G, Sokal EM, Murray KF, Wirth S. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology. 2020;71:31-43. [PMID: 31222783 DOI: 10.1002/hep.30821] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
513 Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. PLoS One 2020;15:e0229239. [PMID: 32155165 DOI: 10.1371/journal.pone.0229239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
514 Correia C, Almeida N, Figueiredo P. Guidelines in Gastroenterology: Careful Interpretation Is Essential. GE Port J Gastroenterol. [DOI: 10.1159/000518322] [Reference Citation Analysis]
515 Meyer T, Eberle J, Roß RS, Schüttler CG, Baier M, Buder S, Kohl PK, Münstermann D, Hagedorn HJ, Nick S, Jansen K, Bremer V, Mau M, Brockmeyer NH. [Rapid diagnosis of sexually transmitted infections : Joint statement of DSTIG, RKI, and PEI, as well as the reference centers for HIV, HBV, and HCV and consulting laboratories for Chlamydia, gonococci, and Treponema pallidum]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020;63:1271-86. [PMID: 32930821 DOI: 10.1007/s00103-020-03218-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
516 Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation 2020;104:476-81. [PMID: 31634329 DOI: 10.1097/TP.0000000000003014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
517 Dietz J, Kalinina OV, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat 2020;27:974-86. [DOI: 10.1111/jvh.13322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
518 Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res 2020;48:300060520964659. [PMID: 33111612 DOI: 10.1177/0300060520964659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Ruiz I, Nevers Q, Hernández E, Ahnou N, Brillet R, Softic L, Donati F, Berry F, Hamadat S, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication. Antimicrob Agents Chemother 2020;64:e02078-19. [PMID: 32179525 DOI: 10.1128/AAC.02078-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
520 Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. Eur J Gastroenterol Hepatol 2019;31:1049-56. [PMID: 30807443 DOI: 10.1097/MEG.0000000000001386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
522 Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int 2019;39:1986-98. [PMID: 31172639 DOI: 10.1111/liv.14168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
523 Lawitz E, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, Bennett M, Kemmer N, Morelli G, Zha J, Wang D, Shulman NS, Cohen DE, Reddy KR. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney Int Rep 2019;4:257-66. [PMID: 30775622 DOI: 10.1016/j.ekir.2018.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
524 Abdelbary MS, Samir R, El-nahaas SM, Hosny Shahin RM, El-sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B reactivation following eradication of HCV with direct-acting antiviral drugs (DAAs) in a cohort of patients from different institutions in Egypt. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
525 Hoornenborg E, Coyer L, Boyd A, Achterbergh RCA, Schim van der Loeff MF, Bruisten S, de Vries HJC, Koopsen J, van de Laar TJW, Prins M; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. J Hepatol 2020;72:855-64. [PMID: 31862485 DOI: 10.1016/j.jhep.2019.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
526 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
527 Yuri Y, Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Nishimura T, Iijima H, Nishiguchi S. Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis. J Clin Med 2019;9:E95. [PMID: 31905953 DOI: 10.3390/jcm9010095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
528 Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert Review of Hematology 2020;13:85-94. [DOI: 10.1080/17474086.2020.1686354] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
529 Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). Subst Abuse 2019;13:1178221819835847. [PMID: 30944519 DOI: 10.1177/1178221819835847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
530 Li X, Han J, Lee HW, Yoon YS, Jin Y, Khadka DB, Yang S, Kim M, Cho WJ. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. Bioorg Med Chem 2020;28:115679. [PMID: 32912430 DOI: 10.1016/j.bmc.2020.115679] [Reference Citation Analysis]
531 Krait S, Salgado A, Peluso P, Malanga M, Sohajda T, Benkovics G, Naumann L, Neusüß C, Chankvetadze B, Scriba GKE. Complexation of daclatasvir by single isomer methylated β-cyclodextrins studied by capillary electrophoresis, NMR spectroscopy and mass spectrometry. Carbohydr Polym 2021;273:118486. [PMID: 34560933 DOI: 10.1016/j.carbpol.2021.118486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Suijkerbuijk AWM, van Hoek AJ, Koopsen J, de Man RA, Mangen MJ, de Melker HE, Polder JJ, de Wit GA, Veldhuijzen IK. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country. PLoS One 2018;13:e0207037. [PMID: 30408079 DOI: 10.1371/journal.pone.0207037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
533 Nabatchikova EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Moiseev SV. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. Clin Res Hepatol Gastroenterol 2021;:101714. [PMID: 33930587 DOI: 10.1016/j.clinre.2021.101714] [Reference Citation Analysis]
534 Oraby M, Khorshed A, Abdul-Rahman E, Ali R, Elsutohy MM. A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine. J Pharm Biomed Anal 2019;171:104-10. [PMID: 30981192 DOI: 10.1016/j.jpba.2019.03.065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
535 Ruane P, Strasser SI, Gane EJ, Hyland RH, Shao J, Dvory-Sobol H, Tran T, Stamm LM, Brainard DM, Nyberg L, Shafran S. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study. J Viral Hepat 2019;26:770-3. [PMID: 30663168 DOI: 10.1111/jvh.13067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
536 Wu S, Chu C, Su C, Lin C, Lee S, Wang Y, Lee F, Huang Y, Hou M. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Journal of the Chinese Medical Association 2019;82:693-8. [DOI: 10.1097/jcma.0000000000000148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
537 Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol 2021;74:734-41. [PMID: 33248169 DOI: 10.1016/j.jhep.2020.11.027] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
538 Serranti D, Dodi I, Nicastro E, Cangelosi AM, Riva S, Ricci S, Bartolini E, Trapani S, Mastrangelo G, Vajro P, D'Antiga L, Resti M, Indolfi G. Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2019;69:595-598. [PMID: 31335836 DOI: 10.1097/mpg.0000000000002449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
539 Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. Gut Liver 2020;14:357-67. [PMID: 30970444 DOI: 10.5009/gnl18269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
540 Da BL, Lourdusamy V, Kushner T, Dieterich D, Saberi B. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. Eur J Gastroenterol Hepatol 2021;33:859-61. [PMID: 32541241 DOI: 10.1097/MEG.0000000000001786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
541 Carvalho-Louro DM, Soares EB, Trevizoli JE, Marra TMG, da Cunha ALR, Rodrigues MP, Carvalho-Furtado ACL, Dos Santos BTA, de Assis da Rocha Neves F. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis 2020;20:114. [PMID: 32041537 DOI: 10.1186/s12879-020-4809-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
542 Butt Z, Shah SMA. Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience. Pak J Med Sci 2019;35:409-13. [PMID: 31086524 DOI: 10.12669/pjms.35.2.637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
543 Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. J Gastroenterol Hepatol 2020;35:1420-5. [PMID: 31950525 DOI: 10.1111/jgh.14982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Negro F. Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harb Perspect Med 2020;10:a036921. [PMID: 31636094 DOI: 10.1101/cshperspect.a036921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
545 Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458-465. [PMID: 33303216 DOI: 10.1016/j.jhep.2020.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
546 Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, Gentile I, Sogari F, Pierri P, Surace LA, Morisco F, Tundo P, Brancaccio G, Serviddio G, Gatti P, Termite AP, Di Costanzo GG, Caroleo B, Cozzolongo R, Coppola N, Longo A, Fontanella L, Federico A, Rosato V, Terrenato I, Masarone M. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver Int. 2019;39:1852-1859. [PMID: 31175707 DOI: 10.1111/liv.14170] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
547 Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-75. [PMID: 31981264 DOI: 10.1111/jvh.13265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
548 Hidaka I, Enomoto M, Sato S, Suetsugu A, Matono T, Ito K, Ogawa K, Inoue J, Horino M, Kondo Y, Sakaida I, Korenaga M. Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals. Intern Med 2021;60:337-43. [PMID: 33518608 DOI: 10.2169/internalmedicine.4748-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
549 Cabral BCA, Hoffmann L, Bottaro T, Costa PF, Ramos ALA, Coelho HSM, Villela-Nogueira CA, Ürményi TP, Faffe DS, Silva R. Circulating microRNAs associated with liver fibrosis in chronic hepatitis C patients. Biochem Biophys Rep 2020;24:100814. [PMID: 33015376 DOI: 10.1016/j.bbrep.2020.100814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL; STOP-HCV Consortium. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 2021:S1198-743X(21)00373-6. [PMID: 34245902 DOI: 10.1016/j.cmi.2021.06.042] [Reference Citation Analysis]
551 Grant P, Shumbusho F, Van Nuil JI, Kateera F, Mukherjee J, Kabahizi J, Ntaganda F, Nsanzimana S, Mbituyumuremyi A, Damascene MJ, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Ntirenganya C, Gupta N. Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Hepatol Commun 2020;4:569-76. [PMID: 32258951 DOI: 10.1002/hep4.1482] [Reference Citation Analysis]
552 Sise ME, McQuaid T, Martin P. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. Nephrol Dial Transplant 2021:gfab072. [PMID: 33848334 DOI: 10.1093/ndt/gfab072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
553 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
554 Heil J, Soufidi K, Stals F, Frantzen H, Robroek-Schaecken A, Bakker CM, van Nunen AB, Dukers-Muijrers NHTM, Hoebe CJPA. Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands. Eur J Gastroenterol Hepatol 2020;32:851-6. [PMID: 31688310 DOI: 10.1097/MEG.0000000000001593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
555 Nishikawa H, Yoh K, Enomoto H, Ikeda N, Takashima T, Aizawa N, Nishimura T, Nishiguchi S, Iijima H. Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases. In Vivo 2021;35:363-71. [PMID: 33402485 DOI: 10.21873/invivo.12267] [Reference Citation Analysis]
556 Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr. 2020;70:527-538. [PMID: 31977956 DOI: 10.1097/mpg.0000000000002628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
557 Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
558 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
559 Saludes V, Antuori A, Folch C, González N, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy 2019;74:236-45. [PMID: 31706159 DOI: 10.1016/j.drugpo.2019.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
560 Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology 2020;72:431-40. [DOI: 10.1016/j.jhep.2019.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
561 Piekarska A, Berkan-Kawińska A, Deroń Z, Ciupińska J, Białkowska J. Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report. Clin Exp Hepatol 2020;6:60-2. [PMID: 32166126 DOI: 10.5114/ceh.2020.93059] [Reference Citation Analysis]
562 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology 2021;74:1472-82. [DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
563 Chan H, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, Abu Hassan MR. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.113226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
564 Helfritz FA, Wanders V, Bojkova D, Kuklinski N, Westhaus S, Swoboda S, Minor T, Meuleman P, Paul A, Steinmann E, Ciesek S. Infectivity and stability of hepatitis C virus in different perfusion solutions. Transpl Infect Dis 2019;21:e13135. [PMID: 31246353 DOI: 10.1111/tid.13135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
565 Oestringer BP, Bolivar JH, Claridge JK, Almanea L, Chipot C, Dehez F, Holzmann N, Schnell JR, Zitzmann N. Hepatitis C virus sequence divergence preserves p7 viroporin structural and dynamic features. Sci Rep 2019;9:8383. [PMID: 31182749 DOI: 10.1038/s41598-019-44413-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
566 Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, Ialungo AM, Caruso R, Madeddu G, Sotgiu G, Babudieri S. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90:103055. [PMID: 33310637 DOI: 10.1016/j.drugpo.2020.103055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
567 Mondschein S, Yankovic N, Matus O. The challenges of administering a new treatment: the case of direct-acting antivirals for hepatitis C virus. Public Health 2021;190:116-22. [PMID: 33450632 DOI: 10.1016/j.puhe.2020.02.009] [Reference Citation Analysis]
568 Liu CJ, Tseng KC, Lo CC, Tseng IH, Cheng PN. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. J Formos Med Assoc 2020;119:933-40. [PMID: 31594667 DOI: 10.1016/j.jfma.2019.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
569 Mostafa AM, Saafan HA, Al-Tawashi AS, Kasem MH, Alaa AM, Eltobgy MM, Moubarak AS, Gharib MM, Awwad MA, Omar HM, El-Derany MO. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients. Virus Res 2021;292:198226. [PMID: 33171166 DOI: 10.1016/j.virusres.2020.198226] [Reference Citation Analysis]
570 Moiola L, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P, Comi G, Fasolo MM, Franzetti F, Galli M, Gerevini S, Meroni L, Origoni M, Prosperini L, Puoti M, Scarpazza C, Tortorella C, Zaffaroni M, Riva A. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler 2021;27:331-46. [PMID: 32940121 DOI: 10.1177/1352458520952311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
571 Garcia-Cehic D, Rando A, Rodriguez-Frias F, Gregori J, Costa JG, Carrión JA, Macenlle R, Pamplona J, Castro-Iglesias A, Cañizares A, Tabernero D, Campos C, Buti M, Esteban JI, Quer J. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. J Viral Hepat 2021;28:1319-24. [PMID: 33720484 DOI: 10.1111/jvh.13497] [Reference Citation Analysis]
572 Puente A, Fortea JI, Posadas M, Garcia Blanco A, Rasines L, Cabezas J, Arias Loste MT, Llerena S, Iruzubieta P, Fábrega E, Crespo J. Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. J Clin Med 2019;8:E1242. [PMID: 31426495 DOI: 10.3390/jcm8081242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
573 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
574 van Seyen M, Smolders EJ, van Wijngaarden P, Drenth JPH, Wouthuyzen-Bakker M, de Knegt RJ, Honkoop P, El-Sherif O, Colbers A, Back DJ, Burger DM. Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. J Hepatol 2019;70:552-4. [PMID: 30473264 DOI: 10.1016/j.jhep.2018.10.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
575 Broquetas T, Herruzo-Pino P, Mariño Z, Naranjo D, Vergara M, Morillas RM, Forns X, Carrión JA. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. Liver Int 2021;41:2733-46. [PMID: 34525253 DOI: 10.1111/liv.15058] [Reference Citation Analysis]
576 Paltiel O, Hailu W, Abay Z, Clarfield AM, McKee M. "Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries. Int J Health Policy Manag 2020;9:229-32. [PMID: 32613790 DOI: 10.15171/ijhpm.2019.135] [Reference Citation Analysis]
577 Clemente MG, Antonucci R, Sotgiu G, Dettori M, Piana A, Vajro P. Present and future management of viral hepatitis B and C in children. Clinics and Research in Hepatology and Gastroenterology 2020;44:801-9. [DOI: 10.1016/j.clinre.2020.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
578 Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
579 Baatarkhuu O, Lee JS, Amarsanaa J, Kim DY, Ahn SH, Naranzul N, Enkhtuya D, Choijamts N, Batbayar P, Otgonbayar R, Saruul BU, Gantuul C, Gegeebadrakh B, Tuvshinbayar N, Badamsuren D, Ulzmaa G, Otgonbold J, Han KH. Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. Clin Mol Hepatol 2021;27:125-35. [PMID: 33242929 DOI: 10.3350/cmh.2020.0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 Lédinghen V, Lusivika‐nzinga C, Bronowicki J, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky J, Carrat F, Pol S; The AFEF/ANRS Study Group. Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort. J Viral Hepat 2020;27:964-73. [DOI: 10.1111/jvh.13321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
581 Fontana RJ, Lens S, McPherson S, Elkhashab M, Ankoma-Sey V, Bondin M, Dos Santos AGP, Xue Z, Trinh R, Porcalla A, Zeuzem S. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study. Adv Ther 2019;36:3458-70. [PMID: 31646465 DOI: 10.1007/s12325-019-01123-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
582 Fiore V, Ranieri R, Dell'Isola S, Pontali E, Barbarini G, Prestileo T, Marri D, Starnini G, Sotgiu G, Madeddu G, Babudieri S; SIMSPe Group. Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study. Liver Int 2021;41:271-5. [PMID: 33226730 DOI: 10.1111/liv.14745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
583 Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis 2019;19:300. [PMID: 30940090 DOI: 10.1186/s12879-019-3923-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
584 Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:855-861. [PMID: 31609495 DOI: 10.1111/jgh.14874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
585 Zarębska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, Flisiak R. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Adv Med Sci 2020;65:12-7. [PMID: 31841821 DOI: 10.1016/j.advms.2019.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
586 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Lewandowski Z, Kowalik-Mikołajewska B, Marczyńska M. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva Pediatr (Torino) 2022;74:23-30. [PMID: 33438851 DOI: 10.23736/S2724-5276.20.05881-8] [Reference Citation Analysis]
587 Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. J Viral Hepat 2020;27:505-13. [PMID: 32039536 DOI: 10.1111/jvh.13262] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
588 González-Colominas E, Batlle M, Monge-Escartín I, Duran X, Viu A, de Antonio-Cuscó M, Grau S, Bessa X, Carrión JA. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. Eur J Gastroenterol Hepatol 2021;32:214-22. [PMID: 32195695 DOI: 10.1097/MEG.0000000000001714] [Reference Citation Analysis]
589 Bertino G, Ragusa R, Corsaro LS, Frazzetto E, Messina V, Inguscio L, Lai C, Maglia M, Nunnari A, Caponnetto P. Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). Health Psychol Res 2020;8:9450. [PMID: 33553794 DOI: 10.4081/hpr.2020.9450] [Reference Citation Analysis]
590 Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, Dalekos GN, Koukoulis GK. Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis? J Transl Int Med 2021;9:43-51. [PMID: 33850801 DOI: 10.2478/jtim-2021-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat. 2019;26:263-270. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
592 Pihl AF, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM. High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Sci Rep 2018;8:17505. [PMID: 30504788 DOI: 10.1038/s41598-018-35010-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
593 Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol 2021. [PMID: 34599755 DOI: 10.1002/jmv.27374] [Reference Citation Analysis]
594 Hara T, Ohara T, Taniguchi M, Sakai H, Oka K, Iwai N, Tsuji T, Okuda T, Nagata A, Komaki T, Sakagami J, Kagawa K. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. Intern Med 2021;60:2437-43. [PMID: 33612683 DOI: 10.2169/internalmedicine.6664-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Jang TY, Huang CI, Yeh ML, Liang PC, Tsai PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF, Chuang WL, Yu ML. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. J Gastroenterol Hepatol 2020;35:473-81. [PMID: 31414504 DOI: 10.1111/jgh.14835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
596 Harrington PR, Komatsu TE, Sun H, Naeger LK. Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays. Clin Infect Dis 2020;70:327-30. [PMID: 31075159 DOI: 10.1093/cid/ciz385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
597 Pham LV, Pedersen MS, Fahnøe U, Fernandez-Antunez C, Humes D, Schønning K, Ramirez S, Bukh J. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4. Gut 2021:gutjnl-2020-323585. [PMID: 33833066 DOI: 10.1136/gutjnl-2020-323585] [Reference Citation Analysis]
598 Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection. J Infect Dis 2021:jiab094. [PMID: 33598686 DOI: 10.1093/infdis/jiab094] [Reference Citation Analysis]
599 Messina V, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, Simeone F, Onorato L, Di Caprio G, Pisaturo M, Coppola N. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. J Viral Hepat 2020;27:1437-43. [PMID: 32810330 DOI: 10.1111/jvh.13375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
600 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
601 Pokorska-Śpiewak M, Dobrzeniecka A, Lipińska M, Tomasik A, Aniszewska M, Marczyńska M. Liver Fibrosis Evaluated With Transient Elastography in 35 Children With Chronic Hepatitis C Virus Infection. Pediatr Infect Dis J 2021;40:103-8. [PMID: 33021594 DOI: 10.1097/INF.0000000000002913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
602 Wahyuni TS, permatasari AA, Widiandani T, Fuad A, Widyawaruyanti A, Aoki-utsubo C, Hotta H. Antiviral Activities of Curcuma Genus against Hepatitis C Virus. Natural Product Communications 2018;13:1934578X1801301. [DOI: 10.1177/1934578x1801301204] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
603 Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
604 Chi X, Wang M, Pan Y, Jiang J, Jiang T, Yan H, Wu R, Wang X, Gao X, Niu J. Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon. J Gastroenterol Hepatol 2020;35:97-103. [PMID: 31359493 DOI: 10.1111/jgh.14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
605 Pawlotsky JM. Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med 2020;10:a036855. [PMID: 31964653 DOI: 10.1101/cshperspect.a036855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
606 Szereday L, Meggyes M, Berki T, Miseta A, Farkas N, Gervain J, Par A, Par G. Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C. Clin Exp Med 2020;20:219-30. [PMID: 32108916 DOI: 10.1007/s10238-020-00618-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
607 Makhlouf NA, Abdelmalek MO, Ibrahim ME, Abu-Faddan NH, Kheila AE, Mahmoud AA. Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness. J Pediatric Infect Dis Soc. 2021;10:7-13. [PMID: 32060510 DOI: 10.1093/jpids/piaa006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
608 Rial-Crestelo D, Sepúlveda MA, González-Gasca FJ, Geijo-Martínez P, Martínez-Alfaro E, Barberá JR, Yzusqui M, Casallo S, García M, Muñoz Hornero C, Espinosa-Gimeno A, Torralba M; Grupo de Estudio de Castilla la Manche de enfermedades Infecciosas (GECMEI). Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018). Eur J Gastroenterol Hepatol 2021;32:279-87. [PMID: 33252415 DOI: 10.1097/MEG.0000000000002012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
609 Petzold G, Bremer SCB, Knoop RF, Amanzada A, Raddatz D, Ellenrieder V, Ströbel P, Kunsch S, Neesse A. Noninvasive assessment of liver fibrosis in a real-world cohort of patients with known or suspected chronic liver disease using 2D-shear wave elastography. Eur J Gastroenterol Hepatol 2020;32:1559-65. [PMID: 31922976 DOI: 10.1097/MEG.0000000000001675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
610 Feld JJ. Hepatitis C Virus Diagnostics: The Road to Simplification. Clin Liver Dis (Hoboken) 2018;12:125-9. [PMID: 30988927 DOI: 10.1002/cld.760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
611 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
612 Liu CJ, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Massetto B, Suri V, Camus G, Jiang D, Zhang F, Gaggar A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment. Clin Infect Dis 2021:ciab971. [PMID: 34864948 DOI: 10.1093/cid/ciab971] [Reference Citation Analysis]
613 Douglas MW, Tay ESE, Wang DS, Ong ATL, Wilson C, Phu A, Kok J, Dwyer DE, Bull RA, Lloyd AR, Applegate TL, Dore GJ, Howe AY, Harrigan R, George J. Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatol Commun 2020;4:904-15. [PMID: 32490325 DOI: 10.1002/hep4.1496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
615 Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
616 Przekop D, Klapaczynski J, Grytczuk A, Gruszewska E, Gietka A, Panasiuk A, Golaszewski S, Cylwik B, Chrostek L. Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C. J Clin Med 2021;10:3951. [PMID: 34501398 DOI: 10.3390/jcm10173951] [Reference Citation Analysis]
617 Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ, Mahungu T, Ferro F, Sood C, Freeman C, Phillips C, Dhairyawan R, Burholt R, Sharp H, Ullah S, Gilleece Y, Brown A, Orkin C, Rodger A, Bhagani S. Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom? Clin Infect Dis 2021;72:233-8. [PMID: 32211763 DOI: 10.1093/cid/ciaa021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
618 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
619 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
620 Holeksa J, Magel T, Alimohammadi A, Thiam A, Yung R, Chu L, Truong D, Conway B. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. Int J Drug Policy 2019;72:177-80. [PMID: 31176594 DOI: 10.1016/j.drugpo.2019.05.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
621 Prinsenberg T, Zantkuijl P, Zuilhof W, Davidovich U, Schinkel J, Prins M, van der Valk M. Design and Implementation of a Multilevel Intervention to Reduce Hepatitis C Transmission Among Men Who Have Sex With Men in Amsterdam: Co-Creation and Usability Study. JMIR Form Res 2020;4:e19100. [PMID: 32915157 DOI: 10.2196/19100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
622 Alberti A, Angarano G, Colombo M, Craxì A, Di Marco V, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. Clin Res Hepatol Gastroenterol 2019;43:190-200. [PMID: 30377096 DOI: 10.1016/j.clinre.2018.09.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
623 Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Virol J 2019;16:34. [PMID: 30871566 DOI: 10.1186/s12985-019-1140-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
624 Plaz Torres MC, Lleo A, Aghemo A. Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. Lancet Gastroenterol Hepatol 2019;4:5-6. [PMID: 30527582 DOI: 10.1016/S2468-1253(18)30378-9] [Reference Citation Analysis]
625 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
626 Fang C, Virdee S, Jacob J, Rufai O, Agarwal K, Quaglia A, Quinlan DJ, Sidhu PS. Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison. Ultrasound 2019;27:262-71. [PMID: 31762783 DOI: 10.1177/1742271X19862836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
627 Yu M, Huang C, Wei Y, Lin W, Lin Y, Hsu P, Hsu C, Liu TW, Lee J, Niu S, Huang J, Hung T, Yeh M, Huang C, Liang P, Hsieh M, Chen S, Huang J, Chang J, Chiu Y, Dai C, Hwang S, Chuang W. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). Gut. [DOI: 10.1136/gutjnl-2020-323277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
628 Ogawa E, Nomura H, Nakamuta M, Kawano A, Dohmen K, Kajiwara E, Satoh T, Koyanagi T, Takahashi K, Ooho A, Azuma K, Furusyo N, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis. Hepatol Res 2020;50:174-81. [PMID: 31634412 DOI: 10.1111/hepr.13437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
629 Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver Int 2021. [PMID: 34402183 DOI: 10.1111/liv.15040] [Reference Citation Analysis]
630 Nam JY, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Bae SH, Ki M, Choi HY, Lee EY, Jeong SH. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. Gut Liver 2020;14:207-17. [PMID: 31158950 DOI: 10.5009/gnl19005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
631 Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol 2020;11:710. [PMID: 32508646 DOI: 10.3389/fphar.2020.00710] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
632 Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation. Hepatol Commun. 2018;2:1446-1450. [PMID: 30556034 DOI: 10.1002/hep4.1280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
633 Søholm J, Hansen JF, Mössner B, Røge BT, Lauersen A, Hansen JB, Weis N, Barfod TS, Lunding S, Øvrehus A, Mohey R, Thielsen P, Christensen PB. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. PLoS One 2020;15:e0243725. [PMID: 33301499 DOI: 10.1371/journal.pone.0243725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 2019;98:e17343. [PMID: 31574875 DOI: 10.1097/MD.0000000000017343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
635 Tseng C, Liu W, Chen C, Chang T, Tseng K. Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07326-1] [Reference Citation Analysis]
636 Choudhary NS, Saraf N, Saigal S, Soin AS. Long-term Management of the Adult Liver Transplantation Recipients. J Clin Exp Hepatol 2021;11:239-53. [PMID: 33746450 DOI: 10.1016/j.jceh.2020.06.010] [Reference Citation Analysis]
637 Ganta NM, Gedda G, Rathnakar B, Satyanarayana M, Yamajala B, Ahsan MJ, Jadav SS, Balaraju T. A review on HCV inhibitors: Significance of non-structural polyproteins. Eur J Med Chem 2019;164:576-601. [PMID: 30639895 DOI: 10.1016/j.ejmech.2018.12.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
638 Pisaturo M, Minichini C, Starace M, Caroprese M, Macera M, Brancaccio G, De Pascalis S, Santonicola A, Galeota Lanza A, Zampino R, Cotticelli G, Sagnelli E, Gaeta GB, Coppola N. Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12. Liver Int 2019;39:844-53. [PMID: 30554459 DOI: 10.1111/liv.14025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
639 Sharafi H, Maleki S, Alavian SM. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Res 2019;259:54-61. [PMID: 30401643 DOI: 10.1016/j.virusres.2018.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
640 van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J Viral Hepat 2020;27:1270-83. [PMID: 32964615 DOI: 10.1111/jvh.13399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
641 Pisaturo M, Macera M, Alessio L, Calò F, Coppola N. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses 2019;11:E850. [PMID: 31540223 DOI: 10.3390/v11090850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
642 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases. In Vivo 2021;35:2451-6. [PMID: 34182530 DOI: 10.21873/invivo.12524] [Reference Citation Analysis]
643 Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clin Mol Hepatol 2021;27:186-96. [PMID: 33317251 DOI: 10.3350/cmh.2020.0180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
644 Huang PH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YS, Chao M, Lin CL, Yeh CT. The Defective Allele of Aldehyde Dehydrogenase 2 Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:5735-43. [PMID: 31737110 DOI: 10.7150/jca.33221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
645 Elshimi E, Morad W, Mohamad NE. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs. The Journal of Sexual Medicine 2019;16:402-9. [DOI: 10.1016/j.jsxm.2019.01.309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
646 Murayama A, Tajiri K, Kanegane C, Murakami J, Hayashi Y, Yasuda I. Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia. Case Rep Gastroenterol 2021;15:729-35. [PMID: 34594173 DOI: 10.1159/000518306] [Reference Citation Analysis]
647 Zarębska‐michaluk D, Jaroszewicz J, Buczyńska I, Simon K, Lorenc B, Tudrujek‐zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Janczewska E, Dybowska D, Halota W, Pawłowska M, Pabjan P, Mazur W, Czauż‐andrzejuk A, Berak H, Horban A, Socha Ł, Klapaczyński J, Piekarska A, Blaszkowska M, Belica‐wdowik T, Dobracka B, Tronina O, Deroń Z, Białkowska‐warzecha J, Laurans Ł, Flisiak R. Real‐world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. Journal of Gastroenterology and Hepatology 2020;35:1238-46. [DOI: 10.1111/jgh.14936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
648 Yaccob A, Kridin K, Mari A, Fagoonee S. Cutaneous involvement of hepatitis C virus. Which future after new antiviral drugs? G Ital Dermatol Venereol 2020;155:599-601. [PMID: 33295739 DOI: 10.23736/S0392-0488.20.06713-9] [Reference Citation Analysis]
649 Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. Liver Int. 2019;39:1292-1306. [PMID: 30983083 DOI: 10.1111/liv.14119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
650 Taniyama O, Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Kasai A, Tashima S, Tamai T, Moriuchi A, Ido A. Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b. Hepatol Res 2019;49:239-43. [PMID: 30048035 DOI: 10.1111/hepr.13235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
651 Deng Y, Campbell F, Han K, Theodore D, Deeg M, Huang M, Hamatake R, Lahiri S, Chen S, Horvath G, Manolakopoulos S, Dalekos GN, Papatheodoridis G, Goulis I, Banyai T, Jilma B, Leivers M. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. J Viral Hepat 2020;27:699-708. [PMID: 32096313 DOI: 10.1111/jvh.13282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
652 Goel A, Bhadauria DS, Kaul A, Verma A, Tiwari P, Rungta S, Rai P, Gupta A, Aggarwal R. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant 2021;36:1867-71. [PMID: 33097949 DOI: 10.1093/ndt/gfaa187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
653 Sharafi H, Behnava B, Azizi-Saraji A, Namvar A, Anvar A, Salimi S, Alavian SM. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J 2021;18:199. [PMID: 34620204 DOI: 10.1186/s12985-021-01659-0] [Reference Citation Analysis]
654 Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R, Stahmeyer JT; Collaborators DHC-R. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. Eur J Gastroenterol Hepatol 2019;31:230-40. [PMID: 30325794 DOI: 10.1097/MEG.0000000000001283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
655 Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L, Hayashi N. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol 2020;55:640-52. [DOI: 10.1007/s00535-020-01672-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
656 Tsai TC, Deng ST, Hsu CW. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan. J Med Virol 2020;92:219-26. [PMID: 31599455 DOI: 10.1002/jmv.25605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
657 Calça R, Jorge C, Lebre L, Cacheira E, Querido S, Nascimento C, Adragão T, Bruges M, Weigert A, Machado D. Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus. Nefrologia (Engl Ed) 2020;40:675-6. [PMID: 31937466 DOI: 10.1016/j.nefro.2019.11.005] [Reference Citation Analysis]
658 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
659 Masarone M, Caruso R, Aglitti A, Izzo C, De Matteis G, Attianese MR, Pagano AM, Persico M. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. Dig Liver Dis 2020;52:541-6. [PMID: 32234417 DOI: 10.1016/j.dld.2020.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
660 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
661 Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Can J Gastroenterol Hepatol 2020;2020:8872120. [PMID: 33194875 DOI: 10.1155/2020/8872120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
662 Chen YC, Tseng CW, Tseng KC. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine (Baltimore) 2020;99:e20156. [PMID: 32384505 DOI: 10.1097/MD.0000000000020156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
663 Nafari AH, Ayadi A, Noormohamadi Z, Sakhaee F, Vaziri F, Siadat SD, Fateh A. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms. Infection, Genetics and Evolution 2020;79:104144. [DOI: 10.1016/j.meegid.2019.104144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
664 Zhang J, Sun W, Lin J, Tian Y, Ma L, Zhang L, Zhu Y, Qiu W. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China. BMC Infect Dis 2019;19:645. [PMID: 31324230 DOI: 10.1186/s12879-019-4217-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
665 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
666 Høj SB, Jacka B, Minoyan N, Artenie AA, Bruneau J. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. Int J Drug Policy 2019;72:11-23. [PMID: 31003825 DOI: 10.1016/j.drugpo.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
667 Zuccaro V, Lombardi A, Asperges E, Sacchi P, Bruno R. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opin Drug Metab Toxicol 2020;16:97-101. [PMID: 32003256 DOI: 10.1080/17425255.2020.1721459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
668 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Reference Citation Analysis]
669 Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, Satoh T, Kawano A, Koyanagi T, Ooho A, Takahashi K, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res 2018;159:143-52. [PMID: 30300717 DOI: 10.1016/j.antiviral.2018.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
670 Collett S, Torresi J, Earnest-silveira L, Christiansen D, Elbourne A, Ramsland PA. Probing and pressing surfaces of hepatitis C virus-like particles. Journal of Colloid and Interface Science 2019;545:259-68. [DOI: 10.1016/j.jcis.2019.03.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
671 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
672 Lee DH, Ryu SH, Myung HJ, Shin YJ, Lee SH, Park TY, Moon JS. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. Korean J Gastroenterol 2021;77:88-91. [PMID: 33633000 DOI: 10.4166/kjg.2020.145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. BMC Infect Dis 2021;21:413. [PMID: 33947337 DOI: 10.1186/s12879-021-06053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
674 Marcellin F, Jaquet A, Lazarus JV, Molina P, Carrieri P. Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play. Semin Liver Dis 2021;41:109-16. [PMID: 32851613 DOI: 10.1055/s-0040-1716343] [Reference Citation Analysis]
675 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
676 Limdi JK. Editorial commentary on the Indian Journal of Gastroenterology May-June 2020. Indian J Gastroenterol 2020;39:211-3. [PMID: 32710225 DOI: 10.1007/s12664-020-01077-0] [Reference Citation Analysis]
677 Motomura T, Amirneni S, Diaz-Aragon R, Faccioli LAP, Malizio MR, Coard MC, Kocas-Kilicarslan ZN, Frau C, Haep N, Ostrowska A, Florentino RM, Soto-Gutierrez A. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. J Pers Med 2021;11:619. [PMID: 34208839 DOI: 10.3390/jpm11070619] [Reference Citation Analysis]
678 Li W, Liang J, An J, Liu L, Hou Y, Li L, Zhao W, Cui L, Xue N, Al-dhamin Z, Han T, Nan Y, Zhang L, Granito A. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7395506] [Reference Citation Analysis]
679 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
680 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
681 Yan T, Wang J, Li J, Fu S, Chen Y, Hu C, Zhang R, Tian Z, Zhao F, Dong J, Liu J, Yang Y, Chen T, Zhao Y, He Y. Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents. BMC Infect Dis 2019;19:550. [PMID: 31226947 DOI: 10.1186/s12879-019-4117-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
682 Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore) 2021;100:e26312. [PMID: 34128871 DOI: 10.1097/MD.0000000000026312] [Reference Citation Analysis]
683 Lens S, Lazarus JV. The paediatric population: the forgotten element to eliminating hepatitis C virus. Lancet Gastroenterol Hepatol 2020;5:334-5. [PMID: 31954440 DOI: 10.1016/S2468-1253(19)30405-4] [Reference Citation Analysis]
684 Paolucci S, Novazzi F, Piralla A, Maserati R, Gulminetti R, Novati S, Barbarini G, Sacchi P, Fratini A, Bellotti L, Baldanti F. Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. Infect Drug Resist 2019;12:1975-84. [PMID: 31372005 DOI: 10.2147/IDR.S205282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
685 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13:103-109. [PMID: 30539517 DOI: 10.1007/s12072-018-9915-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
686 Price JC, Brandman D. Updated Hepatitis C Virus Screening Recommendation—A Step Forward. JAMA Intern Med 2020;180:637. [DOI: 10.1001/jamainternmed.2019.7334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
687 Ertekin SS, Morgado-Carrasco D, Forns X, Mascaró JM Jr. Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals. JAMA Dermatol 2020;156:471-2. [PMID: 32129794 DOI: 10.1001/jamadermatol.2020.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
688 Sastre L, Ruiz P, Costa J, Forns X. Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. Int J Infect Dis 2019;79:47-9. [PMID: 30496851 DOI: 10.1016/j.ijid.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
689 Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60. [PMID: 30605721 DOI: 10.1016/j.ijantimicag.2018.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
690 Piedade J, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves Ú, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep 2021;11:11681. [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1] [Reference Citation Analysis]
691 Elshimi E, Sakr N, Morad W, Mohamad NE, Waked I. Direct-acting antiviral drugs improve the female sexual burden associated with chronic HCV infection. Expert Rev Anti Infect Ther 2019;17:919-26. [PMID: 31625425 DOI: 10.1080/14787210.2019.1682551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
692 . Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. AIDS 2020;34:1699-711. [DOI: 10.1097/qad.0000000000002622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
693 Brochado Ó, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S; GESIDA Study Group. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. J Biomed Sci 2021;28:23. [PMID: 33785040 DOI: 10.1186/s12929-021-00718-6] [Reference Citation Analysis]
694 Soria ME, García-Crespo C, Martínez-González B, Vázquez-Sirvent L, Lobo-Vega R, de Ávila AI, Gallego I, Chen Q, García-Cehic D, Llorens-Revull M, Briones C, Gómez J, Ferrer-Orta C, Verdaguer N, Gregori J, Rodríguez-Frías F, Buti M, Esteban JI, Domingo E, Quer J, Perales C. Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection. J Clin Microbiol 2020;58:e01985-20. [PMID: 32999010 DOI: 10.1128/JCM.01985-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
695 Burrage L, Zimmerman H, Higgins S, Param K, Orme C, Mitchell J, O'Beirne J. Performance of simple serum-based tests to exclude cirrhosis prior to hepatitis C treatment in non-hospital settings in Australia. Intern Med J 2021;51:533-9. [PMID: 31994285 DOI: 10.1111/imj.14767] [Reference Citation Analysis]
696 Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol 2021;6:391-400. [PMID: 33857445 DOI: 10.1016/S2468-1253(20)30365-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
697 Eletreby R, Anees M, Naguib M, Kobtan A, Helmy A, Khalaf N, Mansour S, Hassany M, El Akel W, Hashem A, Doss W, Esmat G. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. Expert Rev Gastroenterol Hepatol 2021;15:103-10. [PMID: 32933323 DOI: 10.1080/17474124.2020.1823831] [Reference Citation Analysis]
698 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
699 Hernández-Conde M, Fernández I, Perelló C, Gallego A, Bonacci M, Pascasio JM, Romero-Gómez M, Llerena S, Fernández-Rodríguez C, Castro Urda JL, García Buey L, Carmona I, Morillas RM, García ND, Gea F, Carrión JA, Castellote J, Moreno-Planas JM, Piqueras Alcol B, Molina E, Diago M, Montoliu S, de la Vega J, Menéndez F, Sánchez Ruano JJ, García-Samaniego J, Rosales-Zabal JM, Anton MD, Badia E, Souto-Rodríguez R, Salmeron FJ, Fernández-Bermejo M, Figueruela B, Moreno-Palomares JJ, Calleja JL. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64. [PMID: 30265418 DOI: 10.1111/jvh.13008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [